

Certificate of Mailing

Date of Deposit November 8, 2000

Label Number: EL509048865US

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.

Guy Beardsley

Printed name of person mailing correspondence

Guy Beardsley
Signature of person mailing correspondence

APPLICATION
FOR
UNITED STATES LETTERS PATENT

APPLICANT : WILLIAM M. MITCHELL AND CHARLES W. STRATTON
TITLE : DIAGNOSIS AND MANAGEMENT OF INFECTION
CAUSED BY CHLAMYDIA

00807F 10260460

Date: February 18, 1998 Express Mail Label No. EM 361198659US

Inventors: William M. Mitchell and Charles W. Stratton
Attorney's Docket No.: VDB96-02pA2

DIAGNOSIS AND MANAGEMENT OF INFECTION CAUSED BY CHLAMYDIA

RELATED APPLICATIONS

This application is a Continuation-in-Part of U.S. Application No. 08/911,593 filed on August 14, 1997, which claims the benefit of U.S. Provisional Application Number 60/023,921 filed on August 14, 1996, the entire teachings of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

10 *Chlamydiae* are obligate intracellular microorganisms
which parasitize eukaryotic cells and are ubiquitous
throughout the animal kingdom. Members of the chlamydial
genus are considered bacteria with a unique biphasic
developmental cycle having distinct morphological and
15 functional forms. This developmental growth cycle
alternates between 1) intracellular life forms, of which
two are currently recognized, a metabolically-active,
replicating organism known as the reticulate body (RB) and
a persistent, non-replicating organism known as the cryptic
20 phase; and 2) an extracellular life form that is an
infectious, metabolically-inactive form known as the
elementary body (EB).

EBs are small (300-400 nm) infectious, spore-like forms which are metabolically inactive, non-replicating,

Infection by members of the genus *Chlamydiae* induces a significant inflammatory response at the cellular level. For example, genital lesions produced by *Chlamydia trachomatis* frequently elicit a vigorous influx of lymphocytes, macrophages, and plasma cells, suggesting the development of humoral and cellular immunity. Yet, clinically, the initial infection is frequently varied in symptomatology and may even be asymptomatic. Once fully established, the *Chlamydia* are difficult to eradicate, with frequent relapse following antibiotic therapy. Evidence also indicates that the *Chlamydia* may become dormant and are then shed in quantities too few to reliably detect by culture.

Chlamydia pneumoniae (hereinafter "*C. pneumoniae*") is the most recent addition to the genus *Chlamydiae* and is

the upper and lower respiratory tract and is now recognized as ubiquitous in humans. *C. pneumoniae* is the most recent addition to the genus *Chlamydiae* and is well-accepted as a human pathogen that may be difficult to eradicate by standard antibiotic therapy (Hammerschlag et al., Clin.

15 The current therapy for suspected/confirmed *C. pneumoniae* infection is with a short course (e.g., 2-3 weeks) of a single antibiotic. *C. pneumoniae* is susceptible *in vitro* to tetracycline, erythromycin, clarithromycin, and fluoroquinolones such as ofloxacin and
20 sparfloxacin (Kuo et al., *Antimicrob Agents Chemother* 32:257-258 (1988); Welsh et al., *Antimicrob Agents Chemother* 36:291-294 (1992); Chirgwin et al., *Antimicrob Agents Chemother* 33:1634-1635 (1989); Hammerschlag et al., *Antimicrob Agents Chemother* 36:682-683 (1992); Hammerschlag
25 et al., *Antimicrob Agents Chemother* 36:1573-1574); M.R. Hammerschlag, *Antimicrob Agents Chemother* 38:1873-1878 (1994); M.R. Hammerschlag, *Infect. Med.* pp. 64-71 (1994)). Despite this demonstration of *in vitro* susceptibility, *C. pneumoniae* infections may relapse following antibiotic
30 therapy with these agents. *In vitro* studies on the persistence of *Chlamydiae* despite specific and appropriate antibiotic therapy have suggested that the presence of antibiotics promotes the formation of an intracellular, non-replicative state (Beatty et al., *Microbiol. Rev.*
35 58:686-699 (1994)), typically referred to as the latent or

In view of the chronic and persistent nature of chlamydial infections, there is a need for reliable, accurate methods for diagnosis of pathogenic infection as well as therapeutic approaches to manage the infection. Due to the highly infective nature of *Chlamydia* EBs and their ability to reinfect cells, there is also a need for antichlamydial therapy which totally eradicates this pathogen, thereby preventing the long term sequelae of such chronic infections.

The present invention provides a unique approach for the diagnosis and management of infection by *Chlamydia* species, particularly *C. pneumoniae*. The invention is based upon the discovery that a combination of agents directed toward each of the various stages of the chlamydial life cycle can successfully manage infection and ultimately prevent reinfection/reactivation of the pathogen. Accordingly, one embodiment of the invention pertains to methods of treating infection by a *Chlamydia* species, comprising administering to an individual in need thereof a combination of antichlamydial agents, comprising at least two agents, each of which is effective against a different phase of the chlamydial life cycle. For example, the method can be carried out using agents chosen from among the following groups: a) at least one agent effective against the elementary body phase of the chlamydial life cycle; b) at least one agent effective against the replicating phase of the chlamydial life cycle; and c) at

least one agent effective against the cryptic phase of the chlamydial life cycle. The chlamydial pathogen can be eliminated more rapidly when a combination comprising agents directed against each phase of the chlamydial life cycle is administered. For the purposes of this invention, "cryptic phase" embraces any non-replicating, intracellular form, of which there are a number of distinct stages, including but not limited to intracellular EBs, EBs transforming into RBs and vice versa, miniature RBs, non-replicating RBs and the like.

The invention also pertains to novel combinations of antichlamydial agents and to novel pharmaceutical compositions comprising agents at least two antichlamydial agents, each of which is effective against a different phase of the chlamydial life cycle. For example, the agents can be selected from the group consisting of: a) at least one agent effective against the elementary body phase of the chlamydial life cycle; b) at least one agent effective against the replicating phase of the chlamydial life cycle; and c) at least one agent effective against cryptic phase of the chlamydial life cycle. These compositions and combinations of agents can further comprise one or a combination of adjunct compounds, including anti-inflammatory agents, immunosuppressive agents and vitamin C. Use of the combination of antichlamydial agents or compositions thereof for the manufacture of a medicament for the management of *Chlamydia* infection is also described. In a particular embodiment, the agents can be assembled individually, admixed or instructionally assembled.

The invention also pertains to a novel therapy comprising a specific agent effective against the elementary body phase of the chlamydial life cycle which, if used for a sufficient period of time, allows active

09709201-110800

In order to facilitate patient compliance during a course of therapy, the invention provides a means for packaging therapeutic agents, described herein, for the management of *Chlamydia* infection. For example, a pack can comprise at least two different agents, each of which is effective against a different phase of the chlamydial life cycle. These agents can be selected from the group consisting of: a) at least one agent effective against the elementary body phase of the chlamydial life cycle; b) at least one agent effective against the replicating phase of the chlamydial life cycle; and c) at least one agent effective against the cryptic phase of the chlamydial life cycle. Optional adjunct compounds, as mentioned previously, can likewise be present in the pack. A preferred pack will comprise a plurality of agents that are directed to at least two, but preferably to all, of the stages of the chlamydial life cycle. The pack can provide a unit dosage of the agents or can comprise a plurality of unit dosages, and may be labeled with information, such as the mode and order of administration (e.g., separate, simultaneous or sequential) of each component contained therein.

25 The invention also encompasses a method for evaluating the infection status of an individual and/or the progress of therapy in an individual undergoing therapy for infection caused by *Chlamydia*. The method comprises quantifying antibody titer or other measure to the pathogen and comparing the measure to antibody measure quantified at
30 a time earlier in the therapy, whereby the difference between the measures is indicative of the progress of the therapy. The invention also pertains to a method for monitoring the course of therapy for treating infection by
35 *Chlamydia*, comprising determining presence or absence of

Detection of the presence of *Chlamydia* in a sample of biological material taken from an individual thought to be infected therewith is important in determining the course of therapy and the agents to be used. This can be achieved by detecting the presence of DNA encoding MOMP of *Chlamydia* or other chlamydial genes in the individual. In one aspect of the invention, diseases associated with *Chlamydia* infection, such as inflammatory diseases, autoimmune diseases and diseases in which the individual is immunocompromised, can be treated by managing (e.g., significantly reducing infection or eradicating) the *Chlamydia* infection using the novel approach described herein. Both clinical and serological improvements/resolutions in patient status have been demonstrated.

The invention also pertains to a susceptibility test for identifying agent(s) capable of significantly reducing/eliminating chlamydial infection. The method comprises preparing tissue culture from cell lines; inoculating these cells with *Chlamydia* in the absence of cycloheximide; allowing the *Chlamydia* to infect these cells for several days; adding agent(s) to be tested, which agent(s) is/are replaced as needed for the duration of incubation; isolating chlamydial nucleic acid from the cells; and assessing the presence or absence of chlamydial DNA using a suitable nucleotide amplification assay, such as PCR. Preferably the presence or absence of signal for amplified DNA encoding MOMP of *Chlamydia* or other chlamydial protein is determined. Absence of a signal indicates a reduction in the degree of infection below that which is detectable by nucleic acid amplification techniques and strongly suggests eradication of the

microorganism. The susceptibility tests described herein are particularly useful as a drug screening tool for assessing the activity of single agents or combinations of agents against *Chlamydia* infection.

5 The unique and novel aspect of the susceptibility test described herewithin is that it measures the presence or absence of chlamydial DNA and thus can detect cryptic forms and/or elementary bodies both of which are infectious, yet are not replicating.

10 In one embodiment, a suitable nucleotide assay for identifying agents effective against the cryptic form of chlamydia comprises, in the presence of agent(s) to be tested, subjecting cultured cells to protease/reducing agent (e.g., dithiotreitol (DTT)) and protease digestion or
15 guanidine isothiocyanate (also known as guanidine thiocyanate) for a prescribed period of time; extracting DNA from the treated solution; exposing DNA to appropriate polymerase, dNTPs and primers for DNA amplification of MOMP or other protein of the *Chlamydia* species; and determining
20 the presence or absence of amplified DNA by visualizing the ethidium bromide treated DNA product by gel electrophoresis, for example. In particular embodiments, the *Chlamydia* species is *C. pneumoniae* and the appropriate primers are CHLMOMPDB2 and CHLMOMPCB2.

25 The invention further relates to a method of identifying cells containing the cryptic form of a *Chlamydia* species by a nucleic acid amplification technique (e.g., PCR) comprising subjecting cultured cells to protease digestion; stopping protease activity; exposing
30 cells to appropriate heat-stable DNA polymerase, dNTPs and labeled primers (e.g., 3'-biotin labeled, 5'-biotin labeled) for amplification of DNA encoding MOMP of the *Chlamydia* species; washing the cells; exposing the cells to a reporter molecule (e.g., streptavidin-conjugated signal
35 enzyme); exposing the cells to an appropriate substrate for

09709201-110300

A method of identifying cells containing the cryptic form of *Chlamydia* comprises treating cultured cells, thought to be infected with *Chlamydia*, with a disulfide reducing agent; subjecting cultured cells to protease digestion; exposing cells to appropriate polymerase, dNTPs and primers for DNA amplification of nucleic acid encoding a chlamydial protein; exposing the cells to a reporter molecule enzyme; exposing the cells to an appropriate substrate for the reporter enzyme; and determining the presence of the cryptic form of *Chlamydia* by visualizing the amplified DNA encoding a chlamydial protein. Preferably the amplification technique is PCR and the primers are CHLMOMPDB2 and CHLMOMPCB2 of *Chlamydia pneumoniae*.

A similar method can be used as an assay for identifying an agent which is effective against the cryptic form of *Chlamydia*. Accordingly, the method comprises treating cultured cells grown in the absence of cycloheximide, thought to be infected with *Chlamydia*, with a disulfide reducing agent; allowing the chlamydia to replicate; adding a test agent; subjecting cultured cells to protease digestion; exposing cells to appropriate polymerase, dNTPs and primers for DNA amplification of a chlamydial protein; exposing the cells to a reporter molecule enzyme; exposing the cells to an appropriate substrate for the reporter enzyme; and determining the presence of cryptic form of *Chlamydia* by visualizing the amplified DNA encoding a chlamydial protein, such as MOMP.

Also described is a method of detecting chlamydial elementary bodies in a sample comprising contacting the sample with a disulfide reducing agent before using a DNA

The present invention pertains to methods for clearing biological material infected with *Chlamydia* to produce *Chlamydia*-free cell lines and animals, and to methods of maintaining biological material, e.g, cell lines and animals, such that they remain *Chlamydia*-free. According to the method, a biological material is cleared from *Chlamydia* infection by contacting the biological material with at least two agents, each of which is effective against a different phase of the chlamydial life cycle, until the biological material no longer tests positive for *Chlamydia*. The agents can be selected from the group consisting of a) agents effective against the cryptic phase of the chlamydial life cycle; b) agents effective against the elementary body phase of the chlamydial life cycle; and c) agents effective against the replicating phase of the chlamydial life cycle. In one embodiment, the agent effective against the elementary body phase is a disulfide reducing agent. In another embodiment, the agent effective against the cryptic phase is a nitroaromatic compound, such as nitroimidazoles, nitrofluans, analogs, derivatives and combinations thereof.

The invention also pertains to methods of maintaining a *Chlamydia*-free status in animals and cell lines which

-11-

have been cleared of *Chlamydia* infection by the methods of this invention, or have never been infected, such as their *Chlamydia*-free offspring or progeny. Cells or animals can be maintained as *Chlamydia*-free by maintaining them on antibiotics and/or treating their nutrients and environment to ensure that they are *Chlamydia*-free. Particularly, a source of nutrients to be administered to *Chlamydia*-free cells or animals can be treated to inactivate or remove any chlamydial elementary bodies therefrom. This can be accomplished by exposing the nutrients to gamma irradiation for a period of time and level of exposure adequate to inactivate the elementary bodies. In addition to, or alternatively, a source of nutrients can be passed through a filtration system to physically remove the chlamydial elementary bodies therefrom. Optionally, the source of nutrients can be first treated with a disulfide reducing agent, such as dithiothreitol, before the filtration step is performed. The filter should be of adequate size such that objects larger than 0.5 microns are prevented from passing through.

The invention further pertains to a diagnostic kit or pack comprising an assembly of materials selected from the group consisting of antibiotics, reagents, *Chlamydia*-free cell lines, and combinations thereof, or other materials that would be necessary to perform any of the methods described herein.

The invention further relates to a method of detecting viable *Chlamydia* in a biological material suspected of being contaminated therewith, comprising culturing *Chlamydia*-free cells or animals in the presence of biological material and then determining the presence or absence of viable *Chlamydia* in the culture.

09709201-110800

-12-

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B show a sequence alignment of various *Chlamydia* MOMPs.

Figure 2 shows the expressed thioredoxin fusion protein containing a polyhistidine affinity chromatography site, an enterokinase cleavage site, and the full length MOMP protein with an alanine insertion after aal. Amino to carboxyl reads left to right. Total amino acid content in the expressed protein is 530 residues.

Figure 3 illustrates the constant and variable domain (VD) of various *Chlamydia* species.

Figure 4 illustrates the peptide amino acid sequences employed for the construction of peptide based ELISAs with species specificity for VD1.

Figure 5 illustrates the peptides for VD2 which are used similarly to the VD1 sequences.

DETAILED DESCRIPTION OF THE INVENTION

This invention describes specific antichlamydial agents that are used singly or in combination to eliminate or interfere with more than one of the distinct phases of the life cycle of *Chlamydia* species. These chlamydial phases include the intracellular metabolizing/replicating phase; the intracellular cryptic phase; and the extracellular EB phase. Current concepts of susceptibility testing for chlamydiae and antimicrobial therapy for their associated infections address only one phase, the replicating phase. Unless multiple phases of the life cycle are addressed by antichlamydial therapy, the pathogen is likely to escape the desired effects of the antimicrobial agent(s) used and cause recurrent infection after reactivation from latency.

Diagnostic and therapeutic methods for the management of *Chlamydia* infections are described in detail below. For the purposes of this invention, "management of *Chlamydia*

09709201-110800

-13-

infection" is defined as a substantial reduction in the presence of all phases/forms of *Chlamydia* in the infected host by treating the host in such a way as to minimize the sequellae of the infection. *Chlamydia* infections can thus
5 be managed by a unique approach referred to herein as "combination therapy" which is defined for the purpose of this application as the administration of multiple agents which together are directed at least two but preferably each of the multiple phases of the chlamydial life cycle,
10 each agent taken separately, simultaneously or sequentially over the course of therapy. When used alone, these agents are unable to eliminate chlamydial infection. The diagnostic methods and combination therapies described below are generally applicable for infection caused by any
15 *Chlamydia* species, such as *C. pneumoniae*, *C. trachomatis*, *C. psittaci* and *C. pecorum*. Infections in which the causative agent is *C. pneumoniae* are emphasized.

Antichlamydial agents, which have been identified as effective against *Chlamydia* by the susceptibility testing
20 methods described herein, can be used singly or in combination to manage *Chlamydia* infection. For example, compounds identified as anti-cryptic phase drugs, anti-EB phase drugs, anti-DNA-dependent RNA polymerase drugs and nicotinic acid cogener drugs can be used alone or in
25 combination to eliminate, reduce or prevent one or more of the distinct phases of the chlamydial life cycle. These compounds have not heretofore been shown to have antichlamydial activity.

DIAGNOSIS OF CHLAMYDIA INFECTION

30 The invention pertains to methods for diagnosing the presence of *Chlamydia* in a biological material, as well as to the use of these methods to evaluate the serological status of an individual undergoing antichlamydial combination therapy. For purposes of this application,

09709201-110800

"biological material" includes, but is not limited to, bodily secretions, bodily fluids and tissue specimens. Examples of bodily secretions include cervical secretions, trachial-bronchial secretions and pharyngeal secretions.

- 5 Suitable bodily fluids include blood, sweat, tears, cerebral spinal system fluid, serum, urine, synovial fluid and saliva. Animals, cells and tissue specimens such as from a variety of biopsies are embraced by this term.

- 10 In one embodiment, peptide-based assays are disclosed for the detection of one or more immunoglobulins, such as IgG, IgM, IgA and IgE, against antigenic determinants within the full length recombinant MOMP of various *Chlamydia* species. Detection of IgG and/or IgM against antigenic determinants within the full length
- 15 recombinant MOMP of *C. pneumoniae* is preferred. IgA determinations are useful in the analysis of humoral responses to *Chlamydia* in secretions from mucosal surfaces (e.g., lung, GI tract, genitourinary tract, etc.). Similarly, IgG determinations are useful in the analysis of
- 20 allergic manifestations of disease. Table 1 below provides the GenBank Accession numbers of various MOMPs for *Chlamydia* species.

003071-10300

Table 1

	Species	Strain	ID	GenBank Accession No.
	<i>C. trachomatis</i>	A	CTL/A	M33636
	<i>C. trachomatis</i>	A	CTL/A	M58938 M33535
5	<i>C. trachomatis</i>	A	CTL/A	J03813
	<i>C. trachomatis</i>	B	CTL/B	M33636
	<i>C. trachomatis</i>	C	CTL/L	M17343 M19128
	<i>C. trachomatis</i>	D	CTL/D	A27838
	<i>C. trachomatis</i>	E	CTL/E	X52557
10	<i>C. trachomatis</i>	F	CTL/F	X52080 M30501
	<i>C. trachomatis</i>	H	CTL/H	X16007
	<i>C. trachomatis</i>	L1	CTL/L1	M36533
	<i>C. trachomatis</i>	L2	CTL/L2	M14738 M19126
	<i>C. trachomatis</i>	L3	CTL/L3	X55700
15	<i>C. trachomatis</i>	Mouse Pneumo	CTL/MP	X60678
	<i>C. pecorum</i>	Ovine Polyarthritis	CPC/OP	Z18756
	<i>C. psittaci</i>	Strain 6BC	CPS/6B	X56980
	<i>C. psittaci</i>	Feline	CPS/F	X61096
	<i>C. trachomatis</i>	Da	CTL/DA	X62921 S45921
20	<i>C. pneumoniae</i>	TWAR	CPN/HU1	M64064 M34922 M64063
	<i>C. pneumoniae</i> (? <i>C. pecorum</i>)	Horse	CPN/EQ2	L04982
	<i>C. pneumoniae</i>	TWAR	CPN/MS	not assigned
	<i>C. psittaci</i>	Horse	CPS/EQ1	L04982

25 For example, a biological material, such as a sample of tissue and/or fluid, can be obtained from an individual and a suitable assay can be used to assess the presence or amount of chlamydial nucleic acids or proteins encoded

00909201-110600

thereby. Suitable assays include immunological methods such as enzyme-linked immunosorbent assays (ELISA), including luminescence assays (e.g., fluorescence and chemiluminescence), radioimmunoassay, and immunohistology.

5 Generally, a sample and antibody are combined under conditions suitable for the formation of an antibody-protein complex and the formation of antibody-protein complex is assessed (directly or indirectly). In all of the diagnostic methods described herein, the antibodies can

10 be directly labeled with an enzyme, fluorophore, radioisotope or luminescer. Alternatively, antibodies can be covalently linked with a specific scavenger such as biotin. Subsequent detection is by binding avidin or streptavidin labeled with an indicator enzyme, fluorophore,

15 radioisotope, or luminescer. In this regard, the step of detection would be by enzyme reaction, fluorescence, radioactivity or luminescence emission, respectively.

The antibody can be a polyclonal or monoclonal antibody, such as anti-human monoclonal IgG or anti-human

20 monoclonal IgM. Examples of useful antibodies include mouse anti-human monoclonal IgG that is not cross reactive to other immunoglobulins (Pharmagen; Clone G18-145, Catalog No. 34162D); mouse anti-human monoclonal IgM with no cross reactivity to other immunoglobulins (Pharmagen; Clone G20-

25 127, Catalog No. 34152D). Peptide-based immunoassays can be developed which are *Chlamydia* specific or provide species specificity, but not necessarily strain specificity within a species, using monoclonal or polyclonal antibodies that are not cross-reactive to antigenic determinants on

30 MOMP of a chlamydial species not of interest.

Recombinant-based immunological assays have been developed to quantitate the presence of immunoglobulins against the *Chlamydia* species. Full length recombinant *Chlamydia* MOMP can be synthesized using an appropriate

5. expression system, such as in *E. coli* or Baculovirus. The

009709901-110300

5 Diagnosis of chlamydial infection can now be made with
an improved IgM/IgG *C. pneumoniae* method of quantitation
using ELISA techniques, Western blot confirmation of ELISA
specificity and the detection of the MOMP gene of *C.*
pneumoniae in serum using specific amplification primers
10 that allow isolation of the entire gene for analysis of
expected strain-specific differences.

Any known techniques for nucleic acid (e.g., DNA and RNA) amplification can be used with the assays described herein. Preferred amplification techniques are the polymerase chain reaction (PCR) methodologies which comprise solution PCR and *in situ* PCR, to detect the presence or absence of unique genes of *Chlamydia*. Species-specific assays for detecting *Chlamydia* can be designed based upon the primers selected. Examples of suitable PCR amplification primers are illustrated below in Table 2. Examples of preferred primers are illustrated in Table 3.

Table 2
Initial and Terminal Nucleotide Sequences of Chlamydial MOMP Genes
in which entire sequence is known

GenBank Accession No.	ID	Initial Fifty Nucleotides	SEQ ID NO.
M64064/M34922/M64063	CPNHU1	ATGAAAAAACTCTTAAAGTCGGCGTTATTATCCGCCGCATTTGCTGGTTC	1
None	CPNHU2 ^a	ATGAAAAAACTCTTAAAGTCGGCGTTATTATCCGCCGCATTTGCTGGTTC	2
L04982	CPNEQ1	ATGAAAAAACTCTTGAAGTCGGCATTTATTGTTGCCGCTACGGGTTCCGC	3
L04982	CPNEQ2	ATGAAAAAACTCTTAAAGTCGGCGTTATTATCCGCCGCATTTGCTGGTTC	4
X56980	CPS/6B	ATGAAAAAACTCTTGAAATCGGCATTTATTGTTGCCGCTACGGGTTCCGC	5
M36703	CPS/AB1	ATGAAAAAACTCTTGAAATCGGCATTTATTGTTGCCGCTACGGGTTCCGC	6
L39020	CPS/AB2	ATGAAAAAACTCTTGAAATCGGCATTTATTGTTGCCGCTACGGGTTCCGC	7
L25436	CPS/AV/C	ATGAAAAAACTCTTGAAATCGGCATTTATTGTTGCCGCTACGGGTTCCGC	8
X61096	CPS/F	ATGAAAAAACTCTTAAATCGGCATTTATTGTTGCCGCTACGGGTTCCGC	9
M33636/N58938/J03813	CTL/A	ATGAAAAAACTCTTGAAATCGGTATTAGTATTTGCCGCTTGAGTTCTGC	10
M17343/M19128	CTL/C	ATGAAAAAACTCTTGAAATCGGTATTAGTATTTGCCGCTTGAGTTCTGC	11
X62921/S45921	CTL/DA	ATGAAAAAACTCTTGAAATCGGTATTAGTATTTGCCGCTTGAGTTCTGC	12
X52557	CTL/E	ATGAAAAAACTCTTGAAATCGGTATTAGTATTTGCCGCTTGAGTTCTGC	13
X52080/M30501	CTL/F	ATGAAAAAACTCTTGAAATCGGTATTAGTATTTGCCGCTTGAGTTCTGC	14
X16007	CTL/H	ATGAAAAAACTCTTGAAATCGGTATTAGTATTTGCCGCTTGAGTTCTGC	15
M36533	CTL/L1	ATGAAAAAACTCTTGAAATCGGTATTAGTATTTGCCGCTTGAGTTCTGC	16
M14738/M19126	CTL/L2	ATGAAAAAACTCTTGAAATCGGTATTAGTATTTGCCGCTTGAGTTCTGC	17
X55700	CTL/L3	ATGAAAAAACTCTTGAAATCGGTATTAGTATTTGCCGCTTGAGTTCTGC	18
X60678	CTL/MP	ATGAAAAAACTCTTGAAATCGGTATTAGTATTTGCCGCTTGAGTTCTGC	19

008077-10260450

Table 2 (Continued)

Chlamydial			Terminal Fifty Nucleotides		SEQ ID NO.
Species	Strain	ID			
<i>C. pneumoniae</i>	TWAR	CPNHU1	GTTTAATTAACGAGAGAGCTGCTCAGTATCTGGTCAGATTCTAA		20
<i>C. pneumoniae</i>	MS	CPNHU2	GTTTAATTAACGAGAGAGCTGCTCAGTATCTGGTCAGATTCTAA		21
<i>C. psittaci</i>	Horse	CPNEQ1	CAACGTTAATCGACGCTGACAAATGGTCAATCACTGGTGAAGCACGCTTA		22
<i>C. pneumoniae</i>	Horse	CPNEQ2	GTTTAATTAACGAGAGAGCTGCTCAGTATCTGGTCAGATTCTAA		23
<i>C. psittaci</i>	SBE	CPS/6B	AACGTTAATCGACGCTGACAAATGGTCAATCACTGGTGAAGCACGCTTAA		24
<i>C. psittaci</i>	Ewe abortion	CPS/AB1	AACGTTAATCGACGCTGACAAATGGTCAATCACTGGTGAAGCACGCTTAA		25
<i>C. psittaci</i>	Bovine abortion	CPS/AB2	GCTTAATCAATGAAGAGCCGCTCAGTGAATGCTCAATTCTAA		26
<i>C. psittaci</i>	Avian	CPS/AV/C	GCTTAATCAATGAAGAGCTGCTCAGTGAATGCTCAATTCTAA		27
<i>C. psittaci</i>	Feline	CPS/F	GCTTAATCGACGAAAGAGCTGCTCAGTGAATGCTCAATTCTAA		28
<i>C. trachomatis</i>	Hu/A	CTL/A	CGCAGTTACAGTTGAGACTCGCTTGATCGATGAGAGAGCAGTCACGTAA		29
<i>C. trachomatis</i>	Hu/C	CTL/C	GCTTGATCGATGAGAGAGCAGGTACGTAATGCAAAATCCGGTTCTAA		30
<i>C. trachomatis</i>	Hu/Da	CTL/DA	GCTTGATCGATGAGAGAGCAGCTCAGTAAATGCAAAATCCGGTTCTAA		31
<i>C. trachomatis</i>	HU/E	CTL/E	CGCTTGATCGATGAGAGACTGCTCAGTAAATGCAAAATCCGGTTCTAA		32
<i>C. trachomatis</i>	Hu/F	CTL/F	GCTTGATCGATGAGAGAGCTGCTCAGTAAATGCAAAATCCGGTTCTAA		33
<i>C. trachomatis</i>	Hu/H	CTL/H	GCTTGATCGATGAGAGAGCAGCTCAGTAAATGCAAAATCCGGTTCTAA		34
<i>C. trachomatis</i>	Hu/L1	CTL/L1	GCTTGATCGATGAGAGAGCTGCTCAGTAAATGCAAAATCCGGTTCTAA		35
<i>C. trachomatis</i>	Hu/L2	CTL/L2	GCTTGATCGATGAGAGAGCTGCTCAGTAAATGCAAAATCCGGTTCTAA		36
<i>C. trachomatis</i>	Hu/L3	CTL/L3	GCTTGATCGATGAGAGAGCAGCTCAGTAAATGCAAAATCCGGTTCTAA		37
<i>C. trachomatis</i>	Mouse	CTL/MP	GCTTGATCGATGAAGAGCAGCTCAGTAAATGCTCAGTTCCGTTCTAA		38

- a Sequence from a cerebral spinal fluid of a patient with multiple sclerosis isolated by the inventors. Sequence is identical to TWAR *C. pneumoniae* with exception of a C/T mutation at NT 54 and a G/A mutation at NT 126.
- b Terminator codon underlined

00801F" T0260460

Table 3
Primers for PCR Amplification of Entire MOMP Gene ^a

Chlamydia			Plus Strand Primer		SEQ ID NO.
Species	Strain	ID	Sequence	T _m ^b	
<i>C. pneumoniae</i>	TWAR	CHLMOMP DB2	ATGAAAAAAC TCTTAAAGTC GCGGTTATTA TCCGCCGC	61.4°	105
<i>C. trachomatis</i>	L2	CTMOMP L2DB	ATGAAAAAAC TCTTGAAATC GGTATTAGTG TTTGCCGCTT TGAG	61.2°	106
<i>C. psittaci</i>	Feline	PSOMP FPN-D	ATGAAAAAAC TCTTAAATC GGCATTATTA TTTGCCGCTG CGGG	62.1°	107
<i>C. psittaci</i>	6BC	PSOMP 6BC-b	ATGAAAAAAC TCTTGAAATC GGCATTATTG TTTGCCGCTA CGGG	63.0°	108
<i>C. trachomatis</i>	Mouse	CTMU MOMP-D	ATGAAAAAAC TCTTGAAATC GGTATTAGCA TTTGCCGTTT TGGGTTCTGC	63.5°	109

008077-10260450

Table 3 (Continued)
Primers for PCR Amplification of Entire MOMP Gene ^a

Chlamydia			Minus Strand Primer		SEQ ID NO.
Species	Strain	ID	Sequence	T _m ^b	
<i>C. pneumoniae</i>	TWAR	CHLMOMP CB2	TTAGAATCTG AACTGACCAG ATACGTGAGC AGCTCTCTCG	64.4°	110
<i>C. trachomatis</i>	L2	CTMOMP L2CB	TTAGAAGCGG AATTGTGCAT TTACGTGAGC AGCTC	61.5°	111
<i>C. psittaci</i>	Feline	PSOMP FPN_C	TTAGAATCTG AATTGAGCAT TAATGTGAGC AGCTCTTTCG TCG	62.2°	112
<i>C. psittaci</i>	6BC	PSOMP GBC_C	TTAGAATCTG AATTGACCAT TCATGTGAGC AGCTCTTTC A TTGATTAGC G	63.4°	113
<i>C. trachomatis</i>	Mouse	CTMU MOMP_C	TTAGAAACGG AACTGAGCAT TTACGTGAGC TGCTCTTTC A TC	63.2°	114

a All primers amplify under identical amplification conditions: 94°C for 1 min., 58°C for 2 min., 74°C for 3 min., for 35 cycles with 72°C for 10 min. extension of last cycle.

b Melting temperature in degrees Celsius of a nucleic acid isomer based on the equation of Mermur and Doty (*J. Mol. Biol.* 5: 109-118, 1962) where $T_m = 81.5 + 16.6 \log_{10} (Na^+/K^+) + 41 (GC) - 600/L$ where (Na^+/K^+) in the molar cation concentration, GC in the mole fraction of GC and L is the sequence fragment length. (Na^+/K^+) used for computation was 0.05M.

Ligase chain reaction can also be carried out by the methods of this invention; primers/probes therefor can be constructed using ordinary skill. Amplification of the entire MOMP gene is useful for mutational analysis and the production of recombinant MOMP. Shorter primers can be used for specific amplification of most of the MOMP genome with a modification of amplification protocol. For example, a 22bp negative strand primer of the sequence 5'-CAGATACGTG AGCAGCTCTC TC-3' (CPNMOMPC; SEQ ID NO. 39) with a computed $T_m = 55^\circ$ plus a 25bp positive strand primer of the sequence 5'-CTCTTAAAGT CGGCGTTATT ATCCG-3' (CPNMOMPD; SEQ ID NO. 40) with a computed $T_m = 53.9^\circ$ can be used as a primer pair by adjusting the hybridization step in the amplification protocol (Table 2) from 58°C to 50°C . Similarly, smaller regions of MOMP can be amplified by a large variety of primer pairs for diagnostic purposes although the utility of strain identification is reduced and amplification may be blocked if one or both primer pairs hybridize to a region that has been mutated. Extensive experience with the full length MOMP PCR amplification indicates that mutational events within the CHLMOMPD32 and CHLMOMPCB2 hybridization sites are rare or non-existent.

The nucleic acid amplification techniques described above can be used to evaluate the course of antichlamydial therapy. The continued absence of detectable chlamydial DNA encoding MOMP as a function of antichlamydial therapy is indicative of clinical management of the chlamydial infection. Serological improvement can be based upon the current serological criteria for eradication of chronic *Chlamydia* reported below in Table 4.

Table 4

Serological Criteria for Eradication
of Chronic *Chlamydia pneumoniae* Infection

IgM	≤1:25
IgG	Stable titer 1:100
PCR	Negative

5

Preferred PCR techniques are discussed in detail below in the Example Section. In general, solution PCR is

10 carried out on a biological material by first pre-incubating the material in an appropriate reducing agent that is capable of reducing the disulfide bonds which maintain the integrity of the MOMP and other surface proteins of the chlamydial elementary bodies, thereby

15 compromising the outer protective shell of the EBs and allowing protease penetration. Suitable disulfide reducing agents include, but are not limited to, dithiothreitol, succimer, glutathione, DL-penicillamine, D-penicillamine disulfide, 2,2'-dimercaptoadipic acid, 2,3-dimercapto-1-propone-sulfide acid. Appropriate concentrations of these

20 reducing agents can be readily determined by the skilled artisan without undue experimentation using a 10 μ M concentration of dithiothreitol (the preferred reducing agent) as a guideline. Failure to include a reducing agent

25 in the initial step may prevent DNA of EBs from being isolated in the subsequent step. Data presented in Example 1 shows the effects of various reducing agents on the susceptibility of EBs to proteinase K digestion. The *in vitro* data shows that dithiothreitol is most effective at

30 opening EBs for protease digestion.

Once the outer shell of the EBs has been released, the pre-incubated material is subjected to protein digestion using a protease (e.g., proteinase K), or functionally

09709201-110800

equivalent enzyme. The DNA is extracted and subjected to a nucleic acid amplification technique, e.g., PCR. The entire gene or portion thereof containing unique antigenic determinant(s) encoding MOMP or other suitable gene can then be amplified using appropriate primers flanking the gene to be amplified. For example, the gene or portion thereof can be the gene encoding MOMP, OMP-B, GRO-ES, GRO-EL, DNAK, 16S RNA, 23S RNA, the gene encoding ribonuclease-P 76 kd attachment protein or a KDO-transferase gene. In an alternative method, guanidine thiocyanate, at preferably a concentration of 4M, or functionally equivalent reducing denaturant may be substituted for the disulfide reduction/protease steps.

The amplified DNA is then separated and identified by standard electrophoretic techniques. DNA bands are identified using ethidium bromide staining and UV light detection. PCR primers can be designed to selectively amplify DNA encoding MOMP of a particular *Chlamydia* species, such as the MOMP of *C. pneumoniae*, *C. pecorum*, *C. trachomatis*, *C. psittaci* (See Figure 1). Primers that are from about 15-mer to about 40-mer can be designed for this purpose.

For *in situ* PCR, the amplification primers are designed with a reporter molecule conjugated to the 5'-terminus. Suitable reporter molecules are well known and can be used herein. However, biotin-labeled primers are preferred. For the MOMP gene, the primers CHLMOMPDB2 and CHLMOMPCB2 have been engineered with a biotin at the 5'-terminus. For *in situ* PCR, using biotin labels incorporated at the 5'-terminus of the amplification primers, each DNA chain amplification results in each double strand DNA containing 2 molecules of biotin. Alternatively, other specific DNA sequences can be used, although the above-described sequence is the preferred embodiment since the large product produced (1.2 kb)

009709201-110800

-25-

prevents diffusion that may be encountered with smaller DNA amplifications. Similarly, other detection labels can be incorporated (i.e., fluorescein, for example) at the 5'-end or digoxigenin-dUTP (replacement for dTPP) can be incorporated within the amplified DNA. Alternatively to labeling the product, specific hybridization probes to constant regions of the amplified DNA can be used to identify an amplified product. This latter method has particular utility for the construction of automated laboratory equipment for solution-based PCR. For example, streptavidin-coated ELISA plates can be used to capture one or both strands of a biotin 5'-labeled DNA with detection by fluorescence of a fluorescein or other incorporated fluorophore detection probe.

15 CLEARING AND MAINTAINING CHLAMYDIA-FREE ORGANISMS

The present invention provides a unique approach for creating and maintaining animals and cell lines which are free of *Chlamydia* infection. Also described herein are methods for creating nutrients and culture media that are suitable for use with animals and cell lines that have been cleared of *Chlamydia* infection.

Attempts to culture isolates of *C. pneumoniae* from blood and cerebrospinal fluid (CSF) have resulted in the discovery that the continuous cell lines routinely used to cultivate *C. pneumoniae* are cryptically infected with *C. pneumoniae*. These include not only in house stocks of HeLa, HL, H-292, HuEVEC and McCoy cells, but also stocks obtained from the American Type Culture Collection (ATCC), The University of Washington Research Foundation for HL cells, as well as a commercial supplier (Bartells) of H-292 and McCoy cells for the clinical culture of *Chlamydia*. The presence of a cryptic form of *C. pneumoniae* in these cells has been repeatedly demonstrated by solution PCR amplifying the MOMP. In situ PCR in HeLa cells against the MOMP

009709201-110600

demonstrates the MOMP genes to be present in 100% of cells. Nevertheless, fluoroscenated mAb to LPS in McCoy cells does not yield any indication of *Chlamydia* (i.e., reactive against all *Chlamydia*) while fluoroscenated mAb to *C. pneumoniae* MOMP yields a generalized fluorescence throughout the cytoplasm that can be confused with non-specific autofluorescence. Infection with *Chlamydia trachomatis* (Bartells supply) yields the typical inclusion body staining with the LPS mAb (i.e., cross reactive with all species of *Chlamydia*) with no change in cytoplasmic signal with anti-MOMP mAb against *C. pneumoniae*. These findings (solution PCR, *in situ* PCR, mAb reactivity) were interpreted as consistent with a cryptic (non-replicating) infection by *C. pneumoniae* of cells commonly used to culture the organism. Further, virtually all rabbits and mice tested to date have PCR signals for the *C. pneumoniae* MOMP gene.

This creates a currently unrecognized problem of major significance for those clinical labs providing *C. pneumoniae* culture services as well as investigators who now do not know whether their results in animals or in cell culture will be affected by cryptic chlamydial contamination. Clinical and research laboratories currently have no way to determine whether an organism is, in fact, *Chlamydia*-free.

This invention pertains to a method for clearing cells and animals of *C. pneumoniae* and keeping them clear. Clearing them entails contacting the infected organism with agents used singly or in combination to eliminate or interfere with more than one of the distinct phases of the life cycle of *Chlamydia* species. Keeping them clear entails either maintaining them on antibiotics and/or treating their nutrients and environment to ensure they are *Chlamydia*-free. In a preferred embodiment, maintenance conditions comprise a combination of isoniazid (INH) (1

09709201-110800

-27-

μg/ml), metronidazole (1 μg/ml), and dithiothreitol (10 μM) in the culture medium. Media changes are accomplished every 3 days or twice per week. The cells can be removed from the protective solution between 1 and 7 days before they are to be used for culture or other purpose.

These techniques have now made it possible to create a variety of *Chlamydia*-free (CF) organisms, including continuous cell lines called HeLa-CF, HL-CF, H-292-CF, HuEVEC-CF, McCoy-CF, African green monkey and other cell lines that are capable of supporting chlamydial growth. Various CF strains of mice, rabbits and other animal models for research use can be produced.

Because *Chlamydia* is highly infectious, organisms which have been cleared of extracellular, replicating and cryptic infections must be protected from exposure to viable EBs if the organisms are to remain clear. The inventors have discovered that many of the nutrients and other materials used to maintain continuous cell lines are contaminated with viable *Chlamydia* EBs. For example, every lot of fetal calf serum has tested positive for the *Chlamydia* MOMP gene by PCR. Since extensive digestion is required for isolation of the DNA, we have concluded it is bound in EBs. *C. pneumoniae* can also be cultured directly from fetal calf serum. Thus, it is necessary to inactivate EBs in these materials, such as culture media and nutrients, used to maintain the *Chlamydia*-free status of the organism. Collectively these materials are referred to herein as "maintenance materials". In one embodiment, nutrients and culture media are subjected to gamma irradiation to inactivate *Chlamydia* therein. Preferably, the material should be irradiated for a period of time sufficient to expose the material to at least 10,000 rads of gamma radiation. It is important for the material to be contained in vessels that do not absorb high energy radiation. The preferred vessel is plastic. In another

In order to insure that research tools, such as cell lines and animals, remain *Chlamydia*-free, an assay has been designed to evaluate whether an organism is *Chlamydia*-free. The method comprises obtaining a sample of cells or tissue culture; culturing the cells in the absence of cycloheximide and determining the presence or absence of *Chlamydia* nucleic acid by a suitable amplification technique, such as PCR. The absence of nucleic acid amplification signal is indicative that the status of the organism is *Chlamydia*-free.

This invention pertains to novel approaches for the susceptibility testing of *Chlamydia* species that are necessitated by the complex life cycle of the chlamydial pathogen as well as by its diverse, extensive, and heretofore unappreciated ability to cause chronic, cryptic, and persistent systemic infections that are refractory to short duration therapy with conventional single agents.

This invention pertains to novel approaches for the susceptibility testing of *Chlamydia* species that are necessitated by the complex life cycle of the chlamydial pathogen as well as by its diverse, extensive, and heretofore unappreciated ability to cause chronic, cryptic, and persistent systemic infections that are refractory to short duration therapy with conventional single agents.

5 The invention is based upon the discovery that current susceptibility testing methods for *Chlamydiae* do not accurately predict the ability of antimicrobial agents to successfully and totally eradicate chronic chlamydial infections. This is because the current susceptibility testing methods measure only replication of chlamydia and ignores the well-known "cryptic phase" (28-33) in which *Chlamydiae* are not actively replicating. Moreover, it has also been discovered that the so-called "cryptic phase" of *Chlamydiae* includes multiple and different phases. The following are phases of the chlamydial life cycle in which the *Chlamydiae* are not replicating: an initial intranuclear phase in which elementary bodies (EBs) transition to reticulate bodies (RBs), an intracytoplasmic phase in which there is a transition of the RB phenotype to the EB phenotype, an intracytoplasmic phase with a nonreplicating, but metabolizing RB, and intracellular/extracellular EB phases in which there is neither replication nor metabolism. In order to assess the cumulative and long term effect of antimicrobial therapy on these multiple life phases, unique in vitro and in vivo susceptibility test methods have been developed and are described herein.

The term "susceptibility" as used herein is intended to mean a physiological response of an organism to an environmental or chemical stimuli. The desired physiological response to stimuli is one which adversely affects the pathogen's viability to replicate or reside within the host cell and, ideally, would result in the complete elimination (i.e., death) of that pathogen.

A. In Vitro Methodology

One aspect of the invention pertains to methods for evaluating the susceptibility of the distinct phases and stages of the life cycle of *Chlamydia*, to a particular agent(s), particularly the cryptic phase, since prior techniques have failed, heretofore, to appreciate the need for drugs that can clear infected cells of cryptic *Chlamydia*. A preferred drug screening method which accomplished this objective utilizes tissue culture cells, in the absence of cycloheximide in order to encourage cryptic infection. Cryptic infection is uncommon in cells used in standard cell culture susceptibility techniques because *Chlamydia* in cycloheximide-paralyzed cells need not compete with the host cell for metabolites and hence are encouraged to replicate.

The *in vitro* method uses standard tissue culture cells, but without the addition of cycloheximide. Moreover, the chlamydiae are allowed to replicate for several days prior to the addition of at least one test agents. A "test agent" can be any compound to be evaluated as an antichlamydial agent for its ability to significantly reduce the presence of *Chlamydia* in living cells. For example, a test agent can include, but is not limited to, antibiotics, antimicrobial agents, antiparasitic agents, antimalarial agent, disulfide reducing agents and antimycobacterial agents. The test agent(s) is/are replaced when needed for the duration of the incubation time (days to weeks) to ensure that the test agent is present and has not been otherwise degraded. Antimicrobial agent(s) (test agent) is then added to the replicating cells. The antimicrobial agents/growth medium are periodically replaced for the duration of the incubation time, which is preferably weeks rather than days. Finally, the end point after the prolonged incubation time is the complete absence of chlamydial DNA, as determined by a

009709201-110800

nucleic acid amplification technique, such as the polymerase chain reaction (PCR) methodology. Standard nucleic acid amplification techniques (such as PCR) are used to ascertain the presence or absence of signal for chlamydial DNA encoding MOMP or other unique *Chlamydia* protein to determine whether the test agent or combination of agents is/are effective in reducing *Chlamydia* infection. The loss of signal (i.e., below the detectable level of the nucleic acid amplification technique) in cells with antibiotic(s) versus its presence in controls is an indication of efficacy of the agent or combination of agents against *Chlamydia*.

Accordingly, the susceptibility test of this invention can be used to identify an agent or agents which are effective against any particular species of *Chlamydia* and can be used to identify agent(s) effective against the cryptic form of the pathogen, i.e., is capable of inhibiting or eliminating the cryptic form of the pathogen. Agents that are effective against *Chlamydia*, as ascertained by the susceptibility testing protocols described herein, can be used as part of a therapy for the management of *Chlamydia* infections. Suitable therapeutic protocols are described in detail below, with a particular focus on targeting agents toward specific stages of the chlamydial life cycle.

The methods described herein are unique because they evaluate the activity of antimicrobial agents in the absence of cycloheximide which provides a more clinically relevant intracellular milieu. For example, any energy-dependent host cell membrane pumps which might move antimicrobial agents in or out of the cell are inactivated by the use of cycloheximide. The methods described herein are unique because they utilize culture medium which has previously been inactivated. The methods are also unique because they measures the effect of a prolonged duration of

008077-10300

exposure to the antimicrobial agent(s) after the intracellular infection by chlamydiae has become established. Finally, the method is unique because it measures the presence/absence of chlamydial DNA as the endpoint, for example by measuring PCR signal. By using complete eradication of chlamydial DNA as an endpoint, the susceptibility test confirms that all phases of *Chlamydiae* have been eradicated as opposed to merely a temporary halt in replication.

When PCR is the preferred methodology used to evaluate assay endpoint, the PCR method can be enhanced by the unique application of a reducing agent, such as dithiothreitol (DTT), in order to uncoat chlamydial EBs and hence allow exposure of the DNA. In other words, DTT permits the EB coating to rupture. By using an assay for DNA in which EBs are specifically uncoated, the susceptibility test endpoint assesses the presence or absence of EBs as well as the presence or absence of both replicating and nonreplicating RBs. Thus, this approach for chlamydial susceptibility testing allows quantitative antimicrobial susceptibility assays of single and combination agents in which the cumulative effect of the agent(s) on the complete eradication of all life phases is measured. Examples of results obtained with this *in vitro* method are described below.

In one embodiment, a suitable nucleic acid assay for identifying agents effective against the cryptic form of chlamydia comprises, in the presence of agent(s) to be tested, subjecting cultured cells to protease/reducing agent (e.g., dithiotreitol) and protease digestion or guanidine isothiocyanate (also known as guanidine thiocyanate) for a prescribed period of time; extracting DNA from the treated solution; exposing DNA to appropriate polymerase, dNTPs and primers for DNA amplification of MOMP or other protein of the *Chlamydia* species; and determining

09709201-110300

-33-

the presence or absence of amplified DNA by visualizing the ethidium bromide treated DNA product by gel electrophoresis, for example. In particular embodiments, the *Chlamydia* species is *C. pneumoniae* and the appropriate
5 primers are CHLMOMPDB2 and CHLMOMPCB2.

The invention further relates to a method of identifying cells containing the cryptic form of a *Chlamydia* species by a nucleic acid amplification technique (e.g., PCR) comprising subjecting cultured cells to
10 protease digestion; stopping protease activity; exposing cells to appropriate heat-stable DNA polymerase, dNTPs and labeled primers (e.g., 3'-biotin labeled, 5'-biotin labeled) for amplification of DNA encoding MOMP of the *Chlamydia* species; washing the cells; exposing the cells to
15 a reporter molecule (e.g., streptavidin-conjugated signal enzyme); exposing the cells to an appropriate substrate for the reporter molecule (e.g., conjugated enzyme); and visualizing the amplified DNA encoding MOMP by visualizing the product of the reaction.

20 The invention pertains to a method of identifying cells containing the cryptic form of *Chlamydia*. The method comprises treating cultured cells, thought to be infected with *Chlamydia*, with a disulfide reducing agent; subjecting cultured cells to protease digestion; exposing cells to
25 appropriate polymerase, dNTPs and primers for DNA amplification of nucleic acid encoding of a chlamydial protein; exposing the cells to a reporter molecule enzyme; exposing the cells to an appropriate substrate for the reporter enzyme; and determining the presence of the
30 cryptic form of *Chlamydia* by visualizing the amplified DNA encoding a chlamydial protein. Preferably the amplification technique is PCR and the primers are CHLMOMPDB2 and CHLMOMPCB2 of *Chlamydia pneumoniae*.

A similar method can be used as an assay for
35 identifying an agent which is effective against the cryptic

009709201-110300

form of *Chlamydia*. Accordingly, the method comprises treating cultured cells grown in the absence of cycloheximide, thought to be infected with *Chlamydia*, with a disulfide reducing agent; allowing the *Chlamydia* to replicate; adding a test agent; subjecting cultured cells to protease digestion; exposing cells to appropriate polymerase, dNTPs and primers for DNA amplification of a gene encoding chlamydial protein; exposing the cells to a reporter molecule enzyme; exposing the cells to an appropriate substrate for the reporter enzyme; and determining the presence of cryptic form of *Chlamydia* by visualizing the amplified DNA encoding a chlamydial protein, such as MOMP.

A detailed description of primers, PCR techniques and other methodologies useful for the present invention are provided in U.S. Patent Application Serial No. 09/025,596 entitled "Identification of Antigenic Peptide Sequences" (~~Attorney Docket No. VDB98-01~~), filed concurrently herewith; the entire teachings of this application are incorporated herein by reference.

B. In Vivo Methodology

In another aspect of the invention, the susceptibility test can be used to evaluate the status of a human or animal undergoing therapy for the management of *Chlamydia* infection. For example, a biological material is isolated from the human or animal undergoing combination therapy. The biological material is treated such that the *Chlamydia* is isolated therefrom. This chlamydial isolate is allowed to infect *Chlamydia* free cells. These infected cells are then exposed to the combination of agents being used in the individual undergoing combination therapy. Alternatively, the individual's serum containing the antimicrobial agents can be added to the infected cells as a "serum bactericidal test" for intracellular chlamydial infection.

09/025,596

The *in vivo* method uses the murine model although other animals such as rats or rabbits can be used. In this method, mice (or any other animal) are inoculated intranasally with 2×10^5 chlamydial EBs per ml. The inventors have confirmed the work of Yang and colleagues (15) in which intranasal inoculation of chlamydial EBs results in systemic dissemination and, in particular, causes infection of the spleen. The inventors have discovered that this systemic dissemination also results in the presence of EBs in the blood of the mice. Therefore, infectivity can be measured by blood culture or by serum/whole blood PCR for chlamydial DNA. Systemic infection is also confirmed and monitored by the presence of elevated IgM and IgG antibody titers. After the systemic murine infection has been established, antimicrobial agents are given to the mice. This is most easily done by adding the antibiotics to the drinking water. The effect of antichlamydial therapy is monitored by serum/whole blood PCR. When the serum/PCR assay suggests eradication of chlamydiae from the bloodstream, the mice are sacrificed and PCR for chlamydial DNA is done on lung, heart, liver, and spleen homogenates. This method is unique because it measures the complete eradication of all life forms of chlamydiae in known murine target organs for chlamydial infection. This *in vivo* susceptibility method has revealed, for example, that antimicrobial therapy with the triple agents, INH, metronidazole and penicillamine, can completely eradicate *C. pneumoniae* from infected mice in four months. Moreover, following complete eradication of chlamydiae, multiple attempts to reinfect these cured mice via intranasal inoculation have proven unsuccessful. This suggests that effective therapy and complete eradication results in the development of

009709201-110800

-36-

protective immunity, and that effective therapy is therefore a way to create effective immunity.

Performing PCR for chlamydial DNA on homogenates of other organ systems can be used to determine the effectiveness of particular antibiotic combinations in eradicating chlamydial infection in those organ systems. Establishment of prior chlamydial infection of those systems can be done by either biopsy or antibody-enhanced radiological imaging. Alternatively, prior infection can be determined statistically by performing PCR for chlamydial DNA on homogenates of the same organ systems in a similarly inoculated but untreated control population. Organ-specific susceptibility is determined by comparing rates of positive PCR assays in the control and treated populations.

An alternative or complementary method of determining the presence of cryptic chlamydial infections in an animal or cell culture is to expose the culture to chlamydia-stimulating compounds. Such compounds include (but are not limited to) cycloheximide, corticosteroids (such as prednisone) and other compounds which are known to stimulate reactivation of cryptic intracellular infections, and disulfide reducing agents (such as dithiotreitol) and other chemicals which cause EBs to turn into RBs. Once the cryptic forms have entered a more active phase, they can be detected using standard detection techniques such as visual detection of inclusion bodies, immunochemical detection of chlamydial antigen, or reverse transcriptase-PCR.

ANTICHLAMYDIAL THERAPY DIRECTED TOWARD THE INITIAL STAGE OF CHLAMYDIA INFECTION

A number of effective agents that are specifically directed toward the initial phase of chlamydial infection

009709201-110300

(i.e., transition of the chlamydial EB to an RB) have been identified. This growth phase, unlike that of the replicating chlamydial microorganism, which uses host cell energy, involves electrons and electron transfer proteins, as well as nitroreductases. Based upon this, it has been shown that the initial phase of *Chlamydia* infection is susceptible to the antimicrobial effects of nitroimidazoles, nitrofurans and other agents directed against anaerobic metabolism in bacteria.

10 Nitroimidazoles and nitrofurans are synthetic antimicrobial agents that are grouped together because both are nitro (NO₂-) containing ringed structures and have similar antimicrobial effects. These effects require degradation of the agent within the microbial cell such that electrophilic radicals are formed. These reactive electrophilic intermediates then damage nucleophilic protein sites including ribosomes, DNA and RNA. Nitroimidazoles and nitrofurans currently are not considered to possess antimicrobial activity against members of the *Chlamydia* species. This lack of antimicrobial activity, however, is due to the fact that conventional susceptibility testing methods only test for effect on the replicating form of *Chlamydia* species.

25 Examples of suitable nitroimidazoles include, but are not limited to, metronidazole, tinidazole, bamnidazole, benznidazole, flunidazole, ipronidazole, misonidazole, moxnidazole, ronidazole, sulnidazole, and their metabolites, analogs and derivatives thereof.

Metronidazole is most preferred. Examples of nitrofurans that can be used include, but are not limited to, nitrofurantoin, nitrofurazone, nifurtimox, nifuratel, nifuradene, nifurdazil, nifurpirinol, nifuratrone, furazolidone, and their metabolites, analogs and

009709201-110800

derivatives thereof. Nitrofurantoin is preferred within the class of nitrofurans.

Throughout this application and for purposes of this invention, "metabolites" are intended to embrace products of cellular metabolism of a drug in the host (e.g., human or animal) including, but not limited to, the activated forms of prodrugs. The terms "analogs" and "derivatives" are intended to embrace isomers, optically active compounds and any chemical or physical modification of an agent, such that the modification results in an agent having similar or increased, but not significantly decreased, effectiveness against *Chlamydia*, compared to the effectiveness of the parent agent from which the analog or derivative is obtained. This comparison can be ascertained using the susceptibility tests described herein.

Cells to be treated can already be cryptically infected or they can be subjected to stringent metabolic conditions which cause or induce the replicating phase to enter the cryptic phase. Such stringent conditions can include changing environmental/culturing conditions in the instance where the infected cells are exposed to γ -interferon; or by exposing cells to conventional antimicrobial agents (such as macrolides and tetracyclines) which induce this cryptic phase of chlamydial infection in human host cells.

NOVEL ANTICHLAMYDIAL THERAPY DIRECTED TOWARD THE
REPLICATING PHASE OF *CHLAMYDIA* INFECTION

A unique class of antichlamydial agents that is effective against the replicating phase of *Chlamydia* (and possibly against some stages of the cryptic stage) have been identified using the susceptibility tests described herein. This novel class of agents comprises ethambutol and isonicotinic acid congeners which include isoniazid

009709201-110800

(INH), isonicotinic acid (also known as niacin), nicotinic acid, pyrazinamide, ethionamide, and aconiazide; where INH is most preferred. Although these are currently considered effective only for mycobacterial infections, due in part to currently available susceptibility testing methodologies, it has been discovered that these agents, in combination with other antibiotics, are particularly effective against *Chlamydia*. It is believed that the isonicotinic acid congeners target the constitutive production of catalase and peroxidase, which is a characteristic of microorganisms, such as mycobacteria, that infect monocytes and macrophages. *Chlamydia* can also successfully infect monocytes and macrophages.

Using INH to eradicate *Chlamydia* from macrophages and monocytes subsequently assists these cells in their role of fighting infection. However, these agents appear to be less effective, *in vitro*, against the cryptic phase. Thus, ethambutol, INH and other isonicotinic acid congeners ideally should be used in combination with agents that target other phases of the chlamydial life cycle. These isonicotinic acid congeners are nevertheless excellent agents for the long term therapy of chronic/systemic chlamydial infection generally, and in particular to chlamydial infection of endothelial and smooth muscle cells in human blood vessels.

INH and its congeners can be used to clear infection from monocytes and/or macrophages. When monocytes and macrophages are infected by *Chlamydia*, they become debilitated and cannot properly or effectively fight infection. It is believed that, if the chlamydial infection, *per se*, is cleared from these cells, then the monocytes and macrophages can resume their critical roles fighting chlamydial or other infection(s). Thus, patient

008077-10260260

10 THERAPY DIRECTED TOWARD ELEMENTARY BODIES OF *CHLAMYDIA*

[illegible]

During the unique chlamydial life cycle, it is known
30 that metabolically-inactive spore-like EBs are released
into the extracellular milieu. Although these released EBs
are infectious, they may not immediately infect nearby

008077" 10260260

susceptible host cells until appropriate conditions for EB infectivity are present. The result of this delay in infection is the extracellular accumulation of metabolically-inactive, yet infectious, EBs. This produces a second type of chlamydial persistence referred to herein as EB "tissue/blood load". This term is similar in concept to HIV load and is defined herein as the number of infectious EBs that reside in the extracellular milieu. Direct microscopic visualization techniques, tissue cell cultures, and polymerase chain reaction test methods have demonstrated that infectious EBs are frequently found in the blood of apparently healthy humans and animals. This phenomenon is clearly of great clinical importance in chlamydial infections as these metabolically-inactive EBs escape the action of current antichlamydial therapy which is directed only against the replicating intracellular forms of *Chlamydia*. The presence of infectious extracellular EBs after the completion of short term, anti-replicating phase therapy for chlamydial infections has been shown to result in infection relapse. Thus, the duration and nature of antichlamydial therapy required for management of chlamydial infections is, in part, dictated by the extracellular load of EBs. For purposes of this invention, short term therapy can be approximately two to three weeks; long term therapy in contrast is for multiple months.

As described in previous sections, it is also believed that persistence of chlamydial infections, in part, may be due to the presence of the cryptic form of *Chlamydia* within the cells. This cryptic intracellular chlamydial form apparently can be activated by certain host factors such as cortisone (Yang et al., *Infection and Immunity*, 39:655-658 (1983); and Malinverni et al., *The Journal of Infectious*

One such class of disulfide reducing agents are thiol-disulfide exchange agents. Examples of these include, but are not limited to, 2,3-dimercaptosuccinic acid (DMSA; also referred to herein as "succimer"); D,L,- β,β -dimethylcysteine (also known as penicillamine); β -lactam (e.g., penicillins, penicillin G, ampicillin and amoxicillin, which produce penicillamine as a degradation product), cycloserine, dithiotreitol, mercaptoethylamine (e.g., mesna, cysteamine, dimercaptol), N-acetylcysteine, tiopronin, and glutathione. A particularly effective extracellular antichlamydial agent within this class is DMSA which is a chelating agent having four ionizable hydrogens and two highly charged carboxyl groups which prevent its relative passage through human cell membranes.

Penicillamine can also be used as a disulfide reducing agent to eliminate chlamydial EBs. However, the use of penicillamine may cause undesirable side effects. Thus, as an alternative, those β -lactam agents which are metabolized or otherwise converted to penicillamine-like agents *in vivo* (i.e., these agents possess a reducing group) can be orally administered to the human or animal as a means of providing a controlled release of penicillamine derivatives, by acid hydrolysis of the penicillin, under physiologic conditions. The *in vivo* production of penicillamine from the degradation of penicillins undoubtedly accounts for the known *in vitro* ability of penicillins to reduce or prevent the development of infectious chlamydial EBs in cell cultures.

20 CURRENTLY RECOGNIZED AGENTS ACTIVE AGAINST CHLAMYDIA
REPLICATION

As chlamydial RBs transform into EBs, they begin to utilize active transcription of chlamydial DNA and translation of the resulting mRNA. As such, these forms of *Chlamydia* are susceptible to currently used antimicrobial agents. The antichlamydial effectiveness of these agents can be significantly improved by using them in combination with other agents directed at different stages of *Chlamydia* life cycle, as discussed herein.

30 Classes of suitable antimicrobial agents include, but are not limited to, rifamycins (also known as ansamacrolides), quinolones, fluoroquinolones,

-44-

chloramphenicol, sulfonamides/sulfides, azalides, cycloserine, macrolides and tetracyclines. Examples of these agents which are members of these classes, as well as those which are preferred, are illustrated below in Table

5 5.

008077-10260260

the *Chlamydia* life cycle and appear to induce a stringent response in *Chlamydia* causing the replicating phase to transform into cryptic forms. This results in a persistent infection *in vivo* or *in vitro* that can be demonstrated by
5 PCR techniques which assess the presence or absence of chlamydial DNA. Nevertheless, one or more of these currently used agents, or a new agent directed against the replicating phase of *Chlamydia*, should be included as one of the chlamydial agents in a combination therapy in order
10 to slow or halt the transition of the EB to the RB as well as to inhibit chlamydial replication.

DISEASES ASSOCIATED WITH CHLAMYDIAL INFECTION

An association has been discovered between chronic *Chlamydia* infection of body fluids and/or tissues with
15 several disease syndromes of previously unknown etiology in humans which respond to unique antichlamydial regimens described herein. To date, these diseases include Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), Interstitial Cystitis (IC),
20 Fibromyalgia (FM), Autonomic nervous dysfunction (AND, neural-mediated hypotension); Pyoderma Gangrenosum (PG), Chronic Fatigue (CF) and Chronic Fatigue Syndrome (CFS). Other diseases are under investigation. Correlation between *Chlamydia* infection and these diseases has only
25 recently been established as a result of the diagnostic methodologies and combination therapies described herein.

Based on this evidence, published evidence of an association between atherosclerosis and *Chlamydia* (Grupta et al., *Circulation* 96:404-407 (1997)), and an
30 understanding of the impact *Chlamydia* infections have on infected cells and the immune systems, the inventors have discovered a connection between *Chlamydia* and a broad set of inflammatory, autoimmune, and immune deficiency diseases. Thus, the invention describes methods for

003077" T0260260

diagnosing and/or treating disease associated with *Chlamydia* infection, such as autoimmune diseases, inflammatory diseases and diseases that occur in immunocompromised individuals by diagnosing and/or treating the *Chlamydia* infection in an individual in need thereof, using any of the assays or therapies described herein. Progress of the treatment can be evaluated serologically, to determine the presence or absence of *Chlamydia* using for example the diagnostic methods provided herein, and this value can be compared to serological values taken earlier in the therapy. Physical improvement in the conditions and symptoms typically associated with the disease to be treated should also be evaluated. Based upon these evaluating factors, the physician can maintain or modify the antichlamydial therapy accordingly. For example, the physician may change an agent due to adverse side-effects caused by the agent, ineffectiveness of the agent, or for other reason. When antibody titers rise during treatment then alternate compounds should be substituted in order to achieve the lower antibody titers that demonstrate specific susceptibility of the *Chlamydia* to the new regimen. A replacement or substitution of one agent with another agent that is effective against the same life stage of *Chlamydia* is desirable.

The therapies described herein can thus be used for the treatment of acute and chronic immune and autoimmune diseases when demonstrated to have a *Chlamydia* load by the diagnostic procedures described herein which include, but are not limited to, chronic hepatitis, systemic lupus erythematosus, arthritis, thyroidosis, scleroderma, diabetes mellitus, Graves' disease, Beschet's disease and graft versus host disease (graft rejection). The therapies of this invention can also be used to treat any disorders in which a chlamydial species is a factor or co-factor.

00807T-10260460

Thus, the present invention can be used to treat a range of disorders in addition to the above immune and autoimmune diseases when demonstrated to be associated with Chlamydial infection by the diagnostic procedures described
5 herein; for example, various infections, many of which produce inflammation as primary or secondary symptoms, including, but not limited to, sepsis syndrome, cachexia, circulatory collapse and shock resulting from acute or chronic bacterial infection, acute and chronic parasitic
10 and/or infectious diseases from bacterial, viral or fungal sources, such as a HIV, AIDS (including symptoms of cachexia, autoimmune disorders, AIDS dementia complex and infections) can be treated, as well as Wegners Granulomatosis.

15 Among the various inflammatory diseases, there are certain features of the inflammatory process that are generally agreed to be characteristic. These include fenestration of the microvasculature, leakage of the elements of blood into the interstitial spaces, and
20 migration of leukocytes into the inflamed tissue. On a macroscopic level, this is usually accompanied by the familiar clinical signs of erythema, edema, tenderness (hyperalgesia), and pain. Inflammatory diseases, such as chronic inflammatory pathologies and vascular inflammatory
25 pathologies, including chronic inflammatory pathologies such as aneurysms, hemorrhoids, sarcoidosis, chronic inflammatory bowel disease, ulcerative colitis, and Crohn's disease and vascular inflammatory pathologies, such as, but not limited to, disseminated intravascular coagulation,
30 atherosclerosis, and Kawasaki's pathology are also suitable for treatment by methods described herein. The invention can also be used to treat inflammatory diseases such as coronary artery disease, hypertension, stroke, asthma, chronic hepatitis, multiple sclerosis, peripheral
35 neuropathy, chronic or recurrent sore throat, laryngitis,

009709201-110800

tracheobronchitis, chronic vascular headaches (including migraines, cluster headaches and tension headaches) and pneumonia when demonstrated to be pathogenically related to Chlamydia infection.

- 5 Treatable disorders when associated with *Chlamydia* infection also include, but are not limited to, neurodegenerative diseases, including, but not limited to, demyelinating diseases, such as multiple sclerosis and acute transverse myelitis; extrapyramidal and cerebellar
- 10 disorders, such as lesions of the corticospinal system; disorders of the basal ganglia or cerebellar disorders; hyperkinetic movement disorders such as Huntington's Chorea and senile chorea; drug-induced movement disorders, such as those induced by drugs which block CNS dopamine receptors;
- 15 hypokinetic movement disorders, such as Parkinson's disease; Progressive supranucleo palsy; Cerebellar and Spinocerebellar Disorders, such as astructural lesions of the cerebellum; spinocerebellar degenerations (spinal ataxia, Friedreich's ataxia, cerebellar cortical
- 20 degenerations, multiple systems degenerations (Mencel, Dejerine-Thomas, Shi-Drager, and Machado Joseph)); and systemic disorders (Refsum's disease, abetalipoproteemia, ataxia, telangiectasia, and mitochondrial multi-system disorder); demyelinating core disorders, such as multiple
- 25 sclerosis, acute transverse myelitis; disorders of the motor unit, such as neurogenic muscular atrophies (anterior horn cell degeneration, such as amyotrophic lateral sclerosis, infantile spinal muscular atrophy and juvenile spinal muscular atrophy); Alzheimer's disease; Down's
- 30 Syndrome in middle age; Diffuse Lewy body disease; Senile Dementia of Lewy body type; Wernicke-Korsakoff syndrome; chronic alcoholism; Creutzfeldt-Jakob disease; Subacute sclerosing panencephalitis, Hallerrorden-Spatz disease; and Dementia pugilistica, or any subset thereof.

09709201-110300

It is also recognized that malignant pathologies involving tumors or other malignancies, such as, but not limited to leukemias (acute, chronic myelocytic, chronic lymphocytic and/or myelodysplastic syndrome); lymphomas (Hodgkin's and non-Hodgkin's lymphomas, such as malignant lymphomas (Burkitt's lymphoma or Mycosis fungoides)); carcinomas (such as colon carcinoma) and metastases thereof; cancer-related angiogenesis; infantile hemangiomas; alcohol-induced hepatitis. Ocular neovascularization, psoriasis, duodenal ulcers, angiogenesis of the female reproductive tract, can also be treated when demonstrated by the diagnostic procedures described herein to be associated with Chlamydial infection.

An immunocompromised individual is generally defined as a person who exhibits an attenuated or reduced ability to mount a normal cellular or humoral defense to challenge by infectious agents, e.g., viruses, bacterial, fungi and protozoa. Persons considered immunocompromised include malnourished patients, patients undergoing surgery and bone marrow transplants, patients undergoing chemotherapy or radiotherapy, neutropenic patients, HIV-infected patients, trauma patients, burn patients, patients with chronic or resistant infections such as those resulting from myelodysplastic syndrome, and the elderly, all of who may have weakened immune systems. A protein malnourished individual is generally defined as a person who has a serum albumin level of less than about 3.2 grams per deciliter (g/dl) and/or unintentional weight loss greater than 10% of usual body weight.

The course of therapy, serological results and clinical improvements from compassionate antichlamydial therapy in patients diagnosed with the diseases indicated were observed and are reported in Example 5. The data provides evidence to establish that treatment of *Chlamydia* infection

009709201-110800

5 generalized disease class.

OTHER DISEASES OF UNKNOWN ETIOLOGY WITH NEW EVIDENCE FOR A
CHLAMYDIA PNEUMONIAE ETIOLOGY

Both *C. trachomatis* and *C. psittaci* exhibit a protean disease complex dependent on different serovars. One known basis for this diversity to date is the amino acid sequence of the MOMP. Fig. 1 shows a sequence alignment of various *Chlamydia* MOMPs. Note that the size and sequence are relatively homologous except for the four variable regions that are responsible for the serovar (serotype) basis of classification. Further, it has been discovered that *C. pneumoniae* infects blood vessel endothelial cells from which EBs are released in the blood stream. In addition, macrophages are known targets for *C. pneumoniae* and may serve as reservoirs and provide an additional mechanism of transmission. *C. pneumoniae* is thus able to spread throughout the human body, establishing infection in multiple sites and in multiple organ systems. Infected sites may exist for an extended period without inducing symptoms that are noticed by the patient or by an examining physician. Sequence variability of MOMPs or other chlamydial antigens may provide a basis for organ specificity while other chlamydial proteins, such as the 60K and 70K heat shock proteins or LPS, may influence immune response.

30 C. psittaci and C. pecorum are known to cause a host of infections in economically significant animals. Thus, the teachings of this invention are relevant to animals. Throughout this application and for purposes of this invention, "patient" is intended to embrace both humans and

Cattle (kg)		Sheep (kg)	
Year	Sex	Year	Sex
1970	100	100	100
1971	100	100	100
1972	100	100	100
1973	100	100	100
1974	100	100	100
1975	100	100	100
1976	100	100	100
1977	100	100	100
1978	100	100	100
1979	100	100	100
1980	100	100	100
1981	100	100	100
1982	100	100	100
1983	100	100	100
1984	100	100	100
1985	100	100	100
1986	100	100	100
1987	100	100	100
1988	100	100	100
1989	100	100	100
1990	100	100	100
1991	100	100	100
1992	100	100	100
1993	100	100	100
1994	100	100	100
1995	100	100	100
1996	100	100	100
1997	100	100	100
1998	100	100	100
1999	100	100	100
2000	100	100	100
2001	100	100	100
2002	100	100	100
2003	100	100	100
2004	100	100	100
2005	100	100	100
2006	100	100	100
2007	100	100	100
2008	100	100	100
2009	100	100	100
2010	100	100	100
2011	100	100	100
2012	100	100	100
2013	100	100	100
2014	100	100	100
2015	100	100	100
2016	100	100	100
2017	100	100	100
2018	100	100	100
2019	100	100	100
2020	100	100	100
2021	100	100	100
2022	100	100	100
2023	100	100	100
2024	100	100	100
2025	100	100	100
2026	100	100	100
2027	100	100	100
2028	100	100	100
2029	100	100	100
2030	100	100	100
2031	100	100	100
2032	100	100	100
2033	100	100	100
2034	100	100	100
2035	100	100	100
2036	100	100	100
2037	100	100	100
2038	100	100	100
2039	100	100	100
2040	100	100	100
2041	100	100	100
2042	100	100	100
2043	100	100	100
2044	100	100	100
2045	100	100	100
2046	100	100	100
2047	100	100	100
2048	100	100	100
2049	100	100	100
2050	100	100	100
2051	100	100	100
2052	100	100	100
2053	100	100	100
2054	100	100	100
2055	100	100	100
2056	100	100	100
2057	100	100	100
2058	100	100	100
2059	100	100	100
2060	100	100	100
206			

animals. Virtually all rabbits and mice tested to date have PCR signals for *C. pneumoniae*. They can be used as appropriate animal models for treatment using specific combination antibiotics to improve therapy. (Banks et al.,
5 *Ameri. J. of Obstetrics and Gynecology* 138(7Pt2):952-956 (1980)); (Moazed et al., *Am. J. Pathol.* 148(2):667-676 (1996)); (Masson et al., *Antimicrob. Agents Chemother.* 39(9):1959-1964 (1995)); (Pattton et al., *Antimicrob. Agents Chemother.* 37(1):8-13 (1993)); (Stephens et al., *Infect.*
10 *Immun.* 35(2):680-684 (1982)); and (Fong et al., *J. Clin. Microbiol* 35(1):48-52 (1997)).

Coupled with these developments are the recently developed rabbit models of coronary artery disease, where rabbits exposed to *C. pneumoniae* subsequently develop
15 arterial plaques similar to humans (Fong et al., *J. Clin. Microbiol.* 35:48-52 (1997)). Most recently, a study at St. George's Hospital in London found that roughly 3/4 of 213 heart attack victims have significant levels of antibodies to *C. pneumoniae* antibody and that those that have such
20 antibodies achieve significantly lower rates of further adverse cardiac events when treated with antibiotics (Gupta et al., *Circulation* 95:404-407 (1997)). Taken together, these three pieces of evidence (the bacteria found in diseased tissue, inoculation with the bacteria causes
25 diseases, and treating for the bacteria mitigates disease) make a case for a causal connection.

ADJUNCT AGENTS USED IN CONJUNCTION WITH THE COMBINATION THERAPY

In addition to the combination therapies discussed
30 above, other compounds can be co-administered to an individual undergoing antichlamydial therapy for the management of chronic/systemic infection. For example, it may be desirable to include one or a combination of anti-inflammatory agents and/or immunosuppressive agents to

0090767-10300

amelioriate side-effects that may arise in response to a particular antichlamydial agent, e.g., Herxheimer reactions. Initial loading with an anti-inflammatory steroid can be introduced to minimize side-effects of the antichlamydial therapy in those patients in which clinical judgment suggests the possibility of serious inflammatory sequelae.

Suitable anti-inflammatory agents (steroidal and nonsteroidal agents) include, but are not limited to, Prednisone, Cortisone, Hydrocortisone and Naproxin. Preferably the anti-inflammatory agent is a steroidal agent, such as Prednisone. The amount and frequency of administration of these adjunct compounds will depend upon patient health, age, clinical status and other factors readily apparent to the medical professional.

Vitamin C (2 gms bid) has also been introduced based on the report that Vitamin C (ascorbic acid) at moderate intracellular concentrations stimulates replication of *C. trachomatis* (Wang et al., *J. Clin. Micro.* 30:2551-2554 (1992)) as well as its potential effect on biofilm charge and infectivity of the bacterium and specifically the EB (Hancock, R.E.W., *Annual Review in Microbiology*, 38:237-264 (1984)).

MODES OF ADMINISTRATION

Based upon the ability of the combination therapy of this invention to improve both the serological and physical status of a patient undergoing treatment, pharmaceutical compositions or preparations can be made comprising at least two different agents chosen from the following groups: a) at least one agent effective against elementary body phase of chlamydial life cycle (e.g., disulfide reducing agents); b) at least one agent effective against replicating phase of chlamydial life cycle (e.g., antimycobacterial agents); and c) at least one agent

09709201-110300

effective against cryptic phase of chlamydial life cycle (e.g., anerobic bactericidal agents). As discussed in greater detail below, the agents can be formulated in a physiologically acceptable vehicle in a form which will be dependent upon the method in which it is administered.

In another aspect, the invention pertains to a combination of agents comprising at least two agents, each of which is effective against a different phase of the chlamydial life cycle, as previously discussed. The combination of antichlamydial can be used in the management of chlamydial infection or prophylaxis thereof to prevent recurrent infection. The combination of agents can be in the form of an admixture, as a pack (discussed in detail below) or individually, and/or by virtue of the instruction to produce such a combination. It should be understood that combination therapy can comprise multiple agents that are effective within a particular phase of the chlamydial life cycle. The combination of antichlamydial agents can further comprise immunosuppressants, anti-inflammatory agents, vitamin C and combinations thereof.

In a preferred embodiment, if only one antichlamydial agent is elected to be used in an asymptomatic patient to reduce/prevent chronic infection, this agent is a reducing agent, such as penicillamine.

The novel therapeutic methods described herein can be used to ameliorate conditions/symptoms associated with the disease states described above, when the disease is onset or aggravated by infection by *Chlamydia*. The agents of this invention can be administered to animals including, but not limited to, fish, amphibians, reptiles, avians and mammals including humans. Compounds and agents described herein can be administered to an individual using standard methods and modes which are typically routine for the disease state.

009709201-110800

Combination(s) of antichlamydial agents of this invention can be used for the manufacture of a medicament for simultaneous, separate or sequential use in managing chlamydial infection or prophylaxis thereof. The agents
5 can also be used for the manufacture of a medicament for therapy of a disease associated with chlamydia infection, such as autoimmune disease, inflammatory disease, immunodeficiency disease.

The agents can be administered subcutaneously,
10 intravenously, parenterally, intraperitoneally, intradermally, intramuscularly, topically, enteral (e.g., orally), rectally, nasally, buccally, vaginally, by inhalation spray, by drug pump or via an implanted reservoir in dosage formulations containing conventional
15 non-toxic, physiologically acceptable carriers or vehicles. The preferred method of administration is by oral delivery. The form in which it is administered (e.g., syrup, elixir, capsule, tablet, solution, foams, emulsion, gel, sol) will depend in part on the route by which it is administered.
20 For example, for mucosal (e.g., oral mucosa, rectal, intestinal mucosa, bronchial mucosa) administration, via nose drops, aerosols, inhalants, nebulizers, eye drops or suppositories can be used. The compounds and agents of this invention can be administered together with other
25 biologically active agents.

In a specific embodiment, it may be desirable to administer the agents of the invention locally to a localized area in need of treatment; this may be achieved by, for example, and not by way of limitation, local
30 infusion during surgery, topical application (e.g., for skin conditions such as psoriasis), transdermal patches, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including

09709201-1103001

membranes, such as sialastic membranes or fibers. For example, the agent can be injected into the joints.

In a specific embodiment when it is desirable to direct the drug to the central nervous system, techniques which can opportunistically open the blood brain barrier for a time adequate to deliver the drug there through can be used. For example, a composition of 5% mannitose and water can be used. In another embodiment, the agents can be delivered to a fetus through the placenta since many of the agents are small enough to pass through the placental barrier.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically (or prophylactically) effective amount of the agent, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The carrier and composition can be sterile. The formulation should suit the mode of administration.

Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions (e.g., NaCl), alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrrolidone, etc. The pharmaceutical preparations can be sterilized and if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances and the like which do not deleteriously react with the active compounds.

The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering

00907T" 10260760

5

15

35

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such

container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use of sale
5 for human administration. The pack or kit can be labeled with information regarding mode of administration, sequence of drug administration (e.g., separately, sequentially or concurrently), or the like. The pack or kit may also include means for reminding the patient to take the
10 therapy. The pack or kit can be a single unit dosage of the combination therapy or it can be a plurality of unit dosages. In particular, the agents can be separated, mixed together in any combination, present in a single vial or tablet. Agents assembled in a blister pack or other
15 dispensing means is preferred. For the purpose of this invention, unit dosage is intended to mean a dosage that is dependent on the individual pharmacodynamics of each agent and administered in FDA approved dosages in standard time courses.

20 DIAGNOSTIC REAGENTS

The invention also provides a diagnostic reagent pack or kit comprising one or more containers filled with one or more of the ingredients used in the assays of the invention. Optionally associated with such container(s)
25 can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of diagnostic products, which notice reflects approval by the agency of manufacture, use of sale for human administration. The pack or kit can be labeled with
30 information regarding mode of administration, sequence of execution (e.g., separately, sequentially or concurrently), or the like. The pack or kit can be a single unit assay or it can be a plurality of unit assays. In particular, the agents can be separated, mixed together in any combination,

008011-10260/60

present in a single fial or tablet. For the purpose of this invention, unit assays is intended to mean materials sufficient to perform only a single assay.

The invention will be further illustrated by the following non-limiting examples of diagnostic and therapeutic methods. All percentages are by weight unless otherwise specified.

EXAMPLES

EXAMPLE 1

10 POLYMERASE CHAIN REACTION (PCR) FOR THE FULL LENGTH MOMP GENE OF *C. PNEUMONIAE* AND OTHER SPECIES OF *CHLAMYDIA* (DIAGNOSTIC)

a. Solution PCR

Serum, blood or tissue samples were pre-incubated in the presence of 10 μ M dithiothreitol at room temperature for 2 hours to reduce the disulfide bonds and facilitate release of the outer shell of the elementary bodies. CSF and other body fluids are also suitable for use as described. Other suitable reducing agents for use in this step include, but are not limited to, succimer and glutathione (e.g., including, but not limited to, glutathione esters, other analogs and derivatives). The failure to include a reducing agent initially may result in a negative PCR signal following the protease digestion step. Appropriate concentrations of these reducing agents can be readily determined by the skilled artisan without undue experimentation using the 10 μ M concentration of dithiothreitol as a guideline. Alternatively, guanidine isothiocyanate may be substituted for the disulfide reduction/protease step. Table 6 shows the effect of various reducing agents on susceptibility of EBs to

00307-10300

-61-

proteinase K digestion in order to allow DNA extraction for PCR amplification.

00807T" T0250250

Effect of various reducing agents on susceptibility of EBs to proteinase K digestion in order to allow DNA extraction for PCR amplification.

Reducing Agent	Concen- tration	PCR Signal ^a	Reducing Agent	Concen- tration	PCR Signal ^a
Dithiothreitol	10mM 1mM 100μM 10μM 1μM	+	2,3-Dimercapto-1- Propione-sulfide acid	10mM 1mM 100μM 10μM 1μM	- - + - -
Succimer	10mM 1mM 100μM 10μM 1μM	- + + + -	Meso-2,2'-Dimercapto adipic acid	10mM 1mM 100μM 10μM 1μM	+ + + + -
DL-Penicillamine	10mM 1mM 100μM 10μM 1μM	- - + - -	Glutathione	10mM 1mM 100μM 10μM 1μM	- wk+ - +/- +/-
D-Penicillamine disulfide	10mM 1mM 100μM 10μM 1μM	+ - - - -	Control	0	-

a. All assays performed on control serum #1154, which on repeated assay without reducing agents, yields a negative PCR signal for the 1.2kB MOMP gene of *C. pneumoniae*. Analysis on agarose gel with ethidium bromide visualization under UV light.

Serum, blood, or tissue samples are lysed overnight at 37°C in the presence of SDS which inhibits DNases and proteinase K which digests protein (i.e., 2 x cell lysis buffer: 1% SDS, 0.2 M NaCl, 10 mM EDTA, 20 mM Tris-KCl, pH 7.5 plus proteinase K to a final concentration of 20 mg/ml). Following digestion, the lysate is extracted x 1 with phenol followed by chloroform extraction x 2. DNA is precipitated from the final aqueous phase by the addition of 1/10 volume Na acetate (3 M) and 2-2.5 volume of cold ethanol. The DNA is pelleted by centrifugation and the DNA is resuspended in 10-20 ml water with PCR amplification performed in the same microtube. The entire gene of MOMP (1.2 kb) is amplified using the CHLMOMPDB2 coding strand primer (5'-ATGAAAAAAC TCTTAAAGTC GCGTTATTA TCCGCCGC; SEQ ID NO. 41) and the CHLMOMPCB2 complimentary strand primer (5'-TTAGAATCTG AACTGACCAG ATACGTGAGC AGCTCTCTCG; SEQ ID NO. 42). Alternatively, shortened primers can be used by making suitable modifications in the primer:DNA hybridization temperature for PCR detection only. The appropriate primer selection, however, may result in the absence of signal if an unknown strain with mutations in one or both primer binding regions is present. The frequency of positive signals using the preferred primers which amplify the full length MOMP gene suggests that mutations in these regions of *C. pneumoniae* is rare. Standard conditions for this gene product in a 50-µl volume is 35 cycles with 1 second ramp times between steps of 94°C for 1 minute, 58°C for 2 minutes and 74°C for 3 minutes. The PCR reaction used 0.1 mM of each primer in Vent buffer with 200 mM of each dNTP, and 1.0 U Vent DNA polymerase. Amplified DNA is separated and identified by electrophoresis in 1.2% agarose or 6% polyacrylamide gels run in the TBE buffer (88 mM Tris-borate, 89 mM boric acid, 2 mM EDTA) at 120 volts for 1 hour. DNA bands are .

008011-10800

This procedure identifies individual cells containing RB and cryptic forms of *C. pneumoniae*. Cultured cells are adhered to glass slides with formalin, or formalin fixed tissue sections embedded in paraffin are adhered to glass slides and subjected to protease digestion (i.e., pepsin, trypsin, chymotrypsin, or other specific proteases). Each digestion time and pH (i.e., pepsin at pH 2.5 or trypsin at pH 7-8, etc.) with a standard concentration of each protease must be evaluated for each tissue type for optimal digestion times. Protease activity is stopped by washing and/or pH change and the target cells exposed to Taq polymerase, dNTPs, and primers. For the MOMP gene the primers CHLMOMPDB2 and CHLMOMPDB2 have been engineered with a biotin at the 5'-terminus. For *in situ* PCR, using biotin labels incorporated at the 5'-terminus of the amplification primers, each DNA chain amplification results in each double strand DNA containing 2 molecules of biotin. Standard conditions of amplification are identical to solution PCR described above. Following the end of the PCR cycle, the slides are washed and exposed to streptavidin- β -galactosidase (or other streptavidin conjugated signal enzyme). Visualization of the amplified MOMP gene is accomplished by bound enzyme hydrolysis of soluble .

substrate yielding an insoluble product which can then be visualized by standard light microscopy.

Alternatively, other specific DNA sequences, including subsections of the full MOMP gene (e.g., subsections including gene sequences for the peptides in Figure 4) can be used, although the above-described sequence is the preferred embodiment since the large product produced (1.2 kb) prevents diffusion that may be encountered with smaller DNA amplifications. Similarly, other detection labels can be incorporated (i.e., fluorescein, for example) at the 5'-end or dioxigenin & UTP can be incorporated within the amplified DNA. Alternatively to labeling the product, specific hybridization probes to constant regions of the amplified DNA can be used to identify an amplified product. This latter method has particular utility for the construction of automated laboratory equipment for solution-based PCR. For example, strepavidin-coated ELISA plates can be used to capture one or both strands of a biotin 5'-labeled DNA with detection by fluorescence of a fluorescen or other incorporated fluorophore detection probe.

EXAMPLE 2

ENZYME LINKED IMMUNO SORBENT ASSAY (ELISA; DIAGNOSTIC)

a. Recombinant MOMP-Based ELISA

The full length MOMP gene of *C. pneumoniae* was directionally cloned into the pET expression plasmid at the NCOI and NOTI restriction sites using primers to introduce these unique restriction sites into the MOMP ends. Primer sequences are as follows:

CPOMPDNCO (Coding strand): 5'-AGCTTACCAT GGCTAAAAAA
CTCTTAAAGT CGGCGTTATT ATCCG-3' (SEQ ID NO. 43)

CPOMP_CNOT (complimentary strand): 5'-ATATGCGGCC
GCTCATAGAA TCTGAACTGA CCAGATACG-3' (SEQ ID NO. 43)

The construction of the MOMP insert into the pET
expression vector (Novagen, Inc.) yields, on transformation
of permissive *E. coli*, an amino terminal thioredoxin fusion
domain, a polyhistidine for Ni⁺-affinity chromatography, a
solubility sequence of approximately 5 kD, and an
endopeptidase cleavage site which yields a full length MOMP
with a modified amino terminal (as illustrated in Figure 2)
containing an alanine insert between the amino terminal
methionine and the adjacent lysine. Either the full length
expressed recombinant fusion protein or the modified MOMP
following endopeptidase cleavage can be used as the antigen
for a *Chlamydia* species ELISA. Other expression systems in
E. coli or *Baculovirus* can be used for synthesis of the
MOMP protein as the antigen in ELISA. The process is
performed by non-covalent attachment of 50 ng recombinant
MOMP in each well (rows 1-11) of a 96 well microtiter plate
(Immulon 4) in carbonate buffer at pH 9.5 with an overnight
incubation at 4°C. The plate is washed with PBS, 0.15%
Tween20 x 3 and is then blocked with PBS, 1% BSA, 0.15%
Tween, 20 at 300 ml per well for 1 hour at RT and then
washed x 3 with PBS, 0.15% Tween20. Serum is serially
diluted in PBS in triplicate in a separate plate and 50 µl
of each well transferred to corresponding wells of a MOMP
ligand plate, and the following sequence is followed:
incubate at 37°C for 1 hour using a parafilm or other
suitable cover to prevent non-uniform evaporation. Wash
with PBS, 1% FCS, 0.05% NaN₃ x 5. Incubate each well with
a predetermined dilution of biotin conjugated anti-human
monoclonal IgG or monoclonal IgM. Incubate at 37°C for 1
hour with cover. Wash (x 3) with PBS, 1% FCS, 0.05% NaN₃.
Follow with 50 µl strepavidin-alkaline phosphatase .

09709201-110800

conjugate (1:200 in PBS, 1% BSA, 0.15% Tween20) for 1 hour at 37°C with cover. Wash x 3 with PBS, 1% CS (calf serum), 0.05% NaN₃. Color is developed with p-nitrophenyl phosphate in glycine buffer at pH 9.6. The color yield is measured on a microtiter colorimeter using a 405 nm filter. The end point titer is the highest dilution of serum or secretion yielding a color yield >3 SD over background (n=8). Analysis is simplified by computer-generated end point antibody titer or other antibody level measure identification and/or quantity of specific antibody (IgG, IgM, or total Ig) in the test sample using appropriate controls. Other strepavidin or avidin enzyme conjugates can be substituted such as strepavidin peroxidase or strepavidin-galactosidase with an approximate substitute yielding a detectable color for quantitation.

b. Peptide-Based ELISA

The recombinant MOMP-based ELISA described above provides a sensitive method for the quantitation of immunoglobulins against the *Chlamydia* genus in serum, plasma, CSF, and other body fluids. In order to provide ELISA assays that are species- and potentially strain-specific for the various *Chlamydia*, two regions in the MOMP have been identified which show minimal amino acid sequence homologies and which are predicted by computer analysis (Intelligenetics) to be excellent antigenic domains by virtue of hydrophilicity and mobility on the solvent-accessible surface of MOMP. Figure 3 illustrates the constant and variable domain (VD) of the various chlamydial species. The identified species-specific antigenic domains are located in VD1 and VD2. Figure 4 illustrates the peptide amino acid sequences employed for the construction of peptide based ELISAs with species specificity for VD1. Figure 5 illustrates the peptides for VD2 which are used

similarly to the VD1 sequences. ELISA methodology parallels that described above for the recombinant MOMP-based ELISA. In addition, a highly antigenic domain (Figure 6) common to all *Chlamydia* has been identified and
5 was developed as an alternative genus-specific ELISA for the *Chlamydia*. Immunization of rabbits has verified the antigenicity of each peptide to each peptide (Table 7). Monoclonal antibodies have further verified the specificities and antigenicity of each peptide (Table 7) as
10 predicted by computer analysis of the nucleotide-generated amino acid sequence of each species-specific MOMP.

008077" F0260460

Table 7
Antigenic Responses To Peptides From 4 Species Of Chlamydiae Identified
By Hydrophilicity And Peptide Movement As Highly Antigenic

Chlamydiae Species	Peptide ^b	Titer ^a	
		Pre	Post
<i>C. pneumoniae</i>	90-105	100	>3200
<i>C. trachomatis</i> L2	91-106	800	>3200
<i>C. psittaci</i>	92-106	400	>3200
<i>C. trachomatis</i> (mouse)	89-105	0	>3200

Chlamydiae Species	Peptide ^b	Titer ^a	
		Pre	Post
<i>C. pneumoniae</i>	158-171	25	>3200
<i>C. trachomatis</i> L2	159-175	200	>3200
<i>C. psittaci</i>	160-172	100	>3200
<i>C. trachomatis</i> (mouse)	158-171	800	>3200

Chlamydiae Species	Peptide ^b	Titer ^a	
		Pre	Post
<i>C. pneumoniae</i>	342-354	200	>3200
<i>C. trachomatis</i> L2	342-354	100	>3200
<i>C. psittaci</i>	ND ^c		
<i>C. trachomatis</i> (mouse)	ND ^c		

a Reciprocal titer

b Immunogenic peptide and ELISA antigen of specific amino acid sequence
against the indicated pre-immunization and post-immunization rabbit
serum

c ND, not done

Table 8 illustrates reciprocal titers of a polyclonal and monoclonal antibody against *C. trachomatis* cross-reactive against *C. pneumoniae* peptide encompassing amino acids 342-354 and a recombinant full length MOMP from *C. pneumoniae*.

Table 8

Reciprocal titers of a polyclonal and a monoclonal antibody against *C. trachomatis* cross-reactive against *C. pneumoniae* peptide encompassing amino acids 342-354 and a recombinant full length MOMP from *C. pneumoniae*

Antigen	Titer ^a	
	Polyclonal Ab ^b	Monoclonal Ab ^c
CPN Momp ^d	400	0
CPN 90-105 ^e	50	0
CPN 158-171 ^f	50	0
CPN 342-354 ^g	>3200	1600

a Reciprocal titer

b Polyclonal goat Ab from Chemicon Inc. against MOMP of *C. trachomatis*

c Monoclonal Ab (ICN, Inc.) against MOMP of *C. trachomatis*

d *C. pneumoniae* recombinant MOMP

e Amino acid peptide 90-105 of *C. pneumoniae*

f Amino acid peptide 158-171 of *C. pneumoniae*

g Amino acid peptide 342-354 of *C. pneumoniae*

008077 "T0260460

EXAMPLE 3

DETECTION ASSAY METHODS (DIAGNOSTIC)

a. Immunoglobulin (Ig) assay

C. pneumoniae EBs were grown in primary human umbilical vein endothelial cells (HuEVEC; early passage), HeLa 199, or a suitable alternative in the presence of 1 $\mu\text{g/ml}$ cycloheximide at 35°C under 5% CO_2 . Permissive cells were lysed at 3 days, thereby liberating EBs. The latter were harvested from infection flasks, sonicated, and cellular debris were removed after sonication by a low speed centrifugation ($\sim 600 \times g$) for 5 minutes. EBs were pelleted by high speed centrifugation ($30,000 \times g$) for 30 minutes at 4°C. The EB pellet was washed with PBS x1 and was reconstituted in 2 ml PBS per four 25- cm^2 culture flask and sonicated at maximum power for 20 seconds and a 0.5 cycle time using a Braun-Sonic U sonicator. EB protein concentration was determined by the Bradford method and the sonicated infectious EB suspension was rendered non-infectious by the addition of 37% formaldehyde to a final 10% formaldehyde concentration with constant agitation during addition. Formalin-treated EBs were added to 96-well plates at 50 μl per well containing 50 ng EB (total of 5 $\mu\text{g/plate}$) and air dried. The plate was washed with PBS-0.15% Tween20 x3 and was then blocked with PBS-1% BSA-0.15% Tween20 at 300 μl per well for 1 hour at room temperature and then washed x3 with PBS-0.15% Tween20. Serum was serially diluted in PBS in duplicate in a separate plate and 50 μl of each well transferred to corresponding wells of a MOMP ligand plate and the following sequence was followed: incubate at 37°C for 1 hour using a parafilm cover; wash with PBS-1% FCS-0.05% NaN_3 x5; incubate each well with a predetermined dilution of biotin-conjugated, antihuman monoclonal IgG or monoclonal

003077-10260260

IgM; incubate at 37°C for 1 hour with cover; wash (x3) with PBS, 1% FCS, 0.05% NaN₃; follow with 50 µl strepavidin-alkaline phosphatase conjugate (1:200 in PBS-1% BSA-0.15% Tween20) for 1 hour at 37°C with cover; and wash
5 x3 with PBS, 1% CS, 0.05% NaN₃. Color was developed with p-nitrophenyl phosphate in glycine buffer at pH 9.6. The color yield was measured on a Flow microtiter colorimeter using a 405 nm filter. End point titer was the highest dilution of serum or secretion yielding a color yield > 3
10 SD over background (n = 8).

b. Western blot

Western blots were prepared by SDS-PAGE of C. pneumoniae EBs (non-formalin fixed) harvested from infected HuEVEC or HeLa cell lysates, electrophoresed under standard
15 SDS-PAGE conditions, and transferred to nitrocellulose achieved with an active diffusion transfer. Albumin-blocked strips were prepared from nitrocellulose sheets and incubated 1 hour with 1.2 ml of a 1:40 dilution of test serum. Detection was achieved with an alkaline
20 phosphatase-conjugated, mouse anti-human antibody, and developed with 5-bromo-4-chloro-3'-indolyphosphate p-toluidine/nitro-blue tetrazolium chloride (BCIP/NBT, Pierce Chemical Company). Polyclonal animal anti-human antibodies can alternatively be used.

25 c. Antigen Capture Assay for Chlamydial MOMP

The peptides described in Figures 3-5 were conjugated via disulfide bonding to keyhole limpet hemocyanin (KLH) by standard methods (Bernatowicz et al., Anal. Biochem.
155(1):95-102 (1986)). The peptide conjugates in alum were
30 used to generate polyclonal and/or monoclonal antibodies to the species-specific domains of MOMP which is used as a capture antibody in 96 well microtiter plates. Final

09709201-110800

configuration can follow a number of alternative routes to yield quantitation of MOMP in body fluids. The favored configuration utilizes biotin labeled recombinant MOMP in a competition assay with streptavidin/alkaline phosphatase generated color development based on the quantity of biotinylated recombinant MOMP displaced by unlabeled MOMP in body fluids.

EXAMPLE 4

IN VITRO ANTIMICROBIAL SUSCEPTIBILITY TESTING FOR C.

10 PNEUMONIAE

Tissue culture cells containing cryptic phase C. pneumoniae (H-292, HeLa, HEL, HuEVEC, McCoy, etc.) are plated at subconfluency in a 96-well microtiter plate (flasks or plates or other configurations can be alternatively used) and cultured in the presence of various antibiotics (singly and in combination) with the medium changed daily. Analysis of chlamydia activity is carried out by assessing loss of solution PCR signal, or relative activity can be quantified by dilution titer of the starting material using the absence of PCR signal as the endpoint titer (i.e., last dilution to yield specific PCR signal).

Two week exposure of single agents including the fluoroquinolone, ofloxacin, and the macrolide, clarithromycin, at 1 µg/ml failed to clear HeLa cells in culture of a detectable PCR signal for the MOMP gene of Chlamydia pneumoniae. In contrast, triple agents consisting of isoniazid (INH), metronidazole, and penicillamine (1 µg/ml each) resulted in no detectable PCR signal (Table 9). None of these agents, effective in the triple combination, is currently recognized as an anti-chlamydial agent.

00709201-110800

SECRET

- a Cultured in the presence of the indicated antibiotic(s), but with no cycloheximide. Media changes at 48-72 hours.
- b Analysis following 2 week exposure to antimicrobial agents.

a	Cultured in the presence of the indicated antibiotic(s), but with no cycloheximide. changes at 48-72 hours.	Media

b Analysis following 2 week exposure to antimicrobial agents.

Table 10
Susceptibility to Antibiotics for Cryptic
Chlamydia pneumoniae Cultured in HeLa Cells^a by PCR

Antibiotic	Conc (μ g/ml)	PCR 2 week	PCR 4 week
Minocycline	1	pos	pos
Doxycycline	1	pos	pos
Isoniazide	1	pos	pos
TMP/SMZ ^b	100	pos	pos
Minocycline + Metronidazole + penicillamine	1/1/4	pos	pos
Doxycyclin + Metronidazole + penicillamine	1/1/4	pos	neg
Isoniazid + Metronidazole + penicillamine	1/1/4	neg	neg
TMP/SMZ + Metronidazole + penicillamine	100/1/4	pos	neg
Metronidazole	0.25	pos	pos
Clarithromycin	0.25	pos	pos
Rifampin	0.25	pos	pos
Ofloxacin	0.25	pos	pos
Minocycline	0.25	pos	pos
Doxycycline	0.25	pos	pos
TMP/SMZ + Metronidazole	25/0.25	pos	pos
Ofloxacin + Metronidazole	0.25/0.25	pos	pos
Rifampin + Metronidazole + penicillamine	0.25/0.25/4	pos	pos
Rifampin + Metronidazole + Ofloxacin	0.25/0.25/0.25	pos	pos
Clarithromycin + Metronidazole + penicillamine	0.25/0.25/1	pos	neg
Doxycycline + Metronidazole + penicillamine	0.25/0.25/1	pos	pos
Minocycline + Metronidazole + penicillamine	0.25/0.25/1	pos	neg
Isoniazid + Metronidazole + penicillamine	0.25/0.25/1	neg	neg
TMP/SMZ	25	pos	pos
Rifampin + Metronidazole	0.25/0.25	pos	pos
None	0	pos	pos

^a Cultured in the presence of the indicated antibiotics, but with no cycloheximide. Media changes at 48-72 hours. pos = positive; neg = negative

^b TMP/SMZ = trimethoprim/sulfamethoxazole

RESPONSE TO ANTIBIOTIC THERAPY

Table 11 illustrates typical responses to combination antibiotic therapy in a variety of patients with diagnostic evidence of an active infection by *C. pneumoniae*. Unlike typical immune responses to infection with infectious agents, most of the included patients have not only detectable IgM titers against the chlamydial genus but in many cases very high IgM titers. With specific therapy over time the IgM titers generally fall, with a rise in IgG titer (as expected). Correct methods of detecting antibodies against *C. pneumoniae* (Indirect immunofluoresence, IMF) are incapable of accurately identifying high ISM titers against *C. pneumoniae*. Moreover, current procedures are genus specific and not species specific as are peptide-based ELISAs. With clearing of the pathogen, the IgG titers fall. Concomitant with combination antibiotic therapy, there is generally an improvement of patient symptoms associated with the specific diagnosis indicative of evidence of an active chlamydial infection.

09709201-110300

Table 11
Serological and PCR Responses to Combination Antibiotic Therapy

Patient	Diagnosis ^a	Titer IgM IgG		Months of Combination Antibiotic Therapy	PCR	Status
PH	FM	800 3200 800	800 1600 200	6 months	+ + wk+	Asymptomatic
BL	MS	2000 400	500 3200	9 months	+ wk+	Dramatic Improvement
MM	CFS/AND	3200 400	800 1600	1 month	+ +	Improvement; Relapse (non- compliant)
PM	CFS	2000 400	25 800	6 months	+ wk+	Asymptomatic
AM	IBD	800 3200	0 400	6 months	wk+ +	90% Improvement
FO	MS	800 800 400 400	3200 800 800 800	10 months	st+ + wk+ +	Improvement in speeds and bowl contin- ence

Table 11 (Continued)

Patient	Diagnosis ^a	Titer IgM IgG		Months of Combination Antibiotic Therapy	PCR	Status
WM	CF	25	25	Pre-illness serum <--Antibiotics start	wk+	Asymptomatic
		1000	25		st+	
		50	800		+	
		50	1600		wk+	
HM	CF	50	400	6 months	-	Asymptomatic
		2000	100		+	
		3200	3200		+	
CN	CFS	200	800	8 months	wk+	75% Improvement
		3200	800		+	
AN	MS/CFS	400	400		wk+	Strength ↑ Fatigue ↓
		200	3200		st+	
JS	CFS (severe)	2000	2000	5 months	st+	Asymptomatic
		2000	2000		+	
		200	800		-	
AG	IBD	3200	400	9 months	+	Improvement in joint Sx
		800	400		+	
		800	800		+	
		800	400		-	
AT	CF	3200	3200	9 months	+	Asymptomatic
		1600	1600		+	
		1600	1600		+	
		800	800		+	
		400	400		+	

Table 11 (Continued)

Patient	Diagnosis ^a	Titer		Months of Combination Antibiotic Therapy	PCR	Status
		IgM	IgG			
LH	RA	3200 800 200	1600 400 50	6 months	wk+ wk+ +	Improvement
HS	MS	2000 3200 50	400 800 200	5 months	+ + -	Improvement
ST	CFS/FM	>1000 1000 400 800 100	100 100 100 3200 100	7 months	wk+ wk+ + + +	Asymptomatic
RV	CF	1000 400 400	100 1600 400	10 months	+ + -	Asymptomatic

^a CF= Chronic Fatigue < 6 months

CFS=Chronic Fatigue Syndrome

FM=Fibromyalgia

IBD=Inflammatory Bowel Disease

MS=Multiple Sclerosis

AND=Autonomic nervous dysfunction (neural-mediated hypotension)

RA=Rheumatoid Arthritis

IgM >> IgG → immune tolerance to the antigen

IgG >> IgM → successful immune control of the antigen

Although the foregoing description is directed toward Chlamydia, it is merely for exemplary purposes and is not intended to limit the invention thereto. The invention therefore is relevant for other to obligate intracellular pathogens. For example, pathogens that must be in an intracellular location in order to replicate, include but are not limited to prions, viruses, Chlamydiae spp., Mycoplasma spp., Ehrilichia spp., Rickettsia spp., Bartonella spp., Borrelia spp., Toxoplasma gondii, Leishmania spp. and Trypanosomes (e.g., Malaria). Additionally, included are pathogens that are able to survive in an intracellular location and can find a physiologic advantage to do so, for example, Legionella spp., Salmonella spp., Listeria spp., Histoplasma spp., Yersinia spp. and Mycobacteria spp. Intracellular pathogens that are able to utilize selective intracellular locations to enhance survivability and/or pathogenics, are embraced in this invention and include but are not limited to Neisseria spp., Staphylococcus spp., Hemophilus spp., Escherichia coli, Candida spp. and Torulopsis spp.

EQUIVALENTS

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the claims.